

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666
	Filing Date		2024-07-24
	First Named Inventor	Steve CARTT	
	Art Unit		
	Examiner Name	Not Yet Assigned	
	Attorney Docket Number		148570-014311

U.S.PATENTS							Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Patent citation information please click the Add button.							Add	
U.S.PATENT APPLICATION PUBLICATIONS							Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Published Application citation information please click the Add button.							Add	
FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							☐
If you wish to add additional Foreign Patent Document citation information please click the Add button								Add
NON-PATENT LITERATURE DOCUMENTS								Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						T ⁵

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666
	Filing Date		2024-07-24
	First Named Inventor	Steve CARTT	
	Art Unit		
	Examiner Name	Not Yet Assigned	
	Attorney Docket Number		148570-014311

	1	IVATURI et al. "Bioavailability and Tolerability of Intranasal Diazepam in Healthy Adult Volunteers" April 2009, Epilepsy Research 84(2-3): 120-126	☐
--	---	---	--------------------------

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666
	Filing Date		2024-07-24
	First Named Inventor	Steve CARTT	
	Art Unit		
	Examiner Name	Not Yet Assigned	
	Attorney Docket Number		148570-014311

CERTIFICATION STATEMENT

Please see 37 CFR 1.97(e) to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☒ A certification statement is not submitted herewith.

FEE

☐ The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

COPIES

☒ An identification of an earlier application pursuant to 37 CFR 1.98 (d) (1) is attached.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/N. Nicole Endejann/	Date (YYYY-MM-DD)	2024-08-30
Name/Print	N. Nicole Endejann	Registration Number	50,229

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666
	Filing Date		2024-07-24
	First Named Inventor	Steve CARTT	
	Art Unit		
	Examiner Name	Not Yet Assigned	
	Attorney Docket Number		148570-014311

U.S.PATENTS							Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Patent citation information please click the Add button.							Add	
U.S.PATENT APPLICATION PUBLICATIONS							Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Published Application citation information please click the Add button.							Add	
FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							☐
If you wish to add additional Foreign Patent Document citation information please click the Add button								Add
NON-PATENT LITERATURE DOCUMENTS								Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						T ⁵

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666
	Filing Date		2024-07-24
	First Named Inventor	Steve CARTT	
	Art Unit		
	Examiner Name	Not Yet Assigned	
	Attorney Docket Number		148570-014311

1	File History for EP 12801372.9, Based on WO2012/174158 and PCT/US2012/042311, filed 29 January 2019 as EX1040 in IPR2019-00451, IPR2019-00450, IPR2019-00449, Part 3 - pp. 501-662.	☐
2	File History for Non-Provisional Patent Application No. 12/413,439, filed 27 March 2009, 439 FH, filed as EX1007 in IPR2019-00451, IPR2019-00450, IPR2019-00449, Part 1 - pp. 1- 400.	☐
3	File History for Non-Provisional Patent Application No. 12/413,439, filed 27 March 2009, 439 FH, filed as EX1007 in IPR2019-00451, IPR2019-00450, IPR2019-00449, Part 1 - pp. 401-800.	☐
4	File History for Non-Provisional Patent Application No. 12/413,439, filed 27 March 2009, 439 FH, filed as EX1007 in IPR2019-00451, IPR2019-00450, IPR2019-00449, Part 3 - pp. 801-1200.	☐
5	File History for Non-Provisional Patent Application No. 12/413,439, filed 27 March 2009, 439 FH, filed as EX1007 in IPR2019-00451, IPR2019-00450, IPR2019-00449, Part 4 - pp. 1201-1600.	☐
6	File History for Non-Provisional Patent Application No. 12/413,439, filed 27 March 2009, 439 FH, filed as EX1007 in IPR2019-00451, IPR2019-00450, IPR2019-00449, Part 5 - pp. 1601-2000.	☐
7	File History for Non-Provisional Patent Application No. 12/413,439, filed 27 March 2009, 439 FH, filed as EX1007 in IPR2019-00451, IPR2019-00450, IPR2019-00449, Part 6 - pp. 2001-2400.	☐
8	File History for Non-Provisional Patent Application No. 12/413,439, filed 27 March 2009, 439 FH, filed as EX1007 in IPR2019-00451, IPR2019-00450, IPR2019-00449, Part 7 - pp. 2401-2800.	☐
9	File History for Non-Provisional Patent Application No. 12/413,439, filed 27 March 2009, 439 FH, filed as EX1007 in IPR2019-00451, IPR2019-00450, IPR2019-00449, Part 8 - pp. 2801-3200.	☐
10	File History for Non-Provisional Patent Application No. 12/413,439, filed 27 March 2009, 439 FH, filed as EX1007 in IPR2019-00451, IPR2019-00450, IPR2019-00449, Part 9 - pp. 3201-3488.	☐
11	File History for US 8,895,546, Application No. 13/495,942, 546 FH, filed 29 January 2019 as EX1004 in IPR2019-00451, IPR2019-00450, IPR2019-00449, Part 1 - pp. 1-350.	☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666
	Filing Date		2024-07-24
	First Named Inventor	Steve CARTT	
	Art Unit		
	Examiner Name	Not Yet Assigned	
	Attorney Docket Number		148570-014311

12	File History for US 8,895,546, Application No. 13/495,942, 546 FH, filed 29 January 2019 as EX1004 in IPR2019-00451, IPR2019-00450, IPR2019-00449, Part 2 - pp. 351-700.	☐
13	File History for US 8,895,546, Application No. 13/495,942, 546 FH, filed 29 January 2019 as EX1004 in IPR2019-00451, IPR2019-00450, IPR2019-00449, Part 3 - pp. 701-1050.	☐
14	File History for US 8,895,546, Application No. 13/495,942, 546 FH, filed 29 January 2019 as EX1004 in IPR2019-00451, IPR2019-00450, IPR2019-00449, Part 4 - pp. 1051-1400.	☐
15	File History for US 8,895,546, Application No. 13/495,942, 546 FH, filed 29 January 2019 as EX1004 in IPR2019-00451, IPR2019-00450, IPR2019-00449, Part 5 - pp. 1401-1750.	☐
16	File History for US 8,895,546, Application No. 13/495,942, 546 FH, filed 29 January 2019 as EX1004 in IPR2019-00451, IPR2019-00450, IPR2019-00449, Part 6 - pp. 1751-2100.	☐
17	File History for US 8,895,546, Application No. 13/495,942, 546 FH, filed 29 January 2019 as EX1004 in IPR2019-00451, IPR2019-00450, IPR2019-00449, Part 7 - pp. 2101-2450.	☐
18	File History for US 8,895,546, Application No. 13/495,942, 546 FH, filed 29 January 2019 as EX1004 in IPR2019-00451, IPR2019-00450, IPR2019-00449, Part 8 - pp. 2451-2681.	☐
19	File History for US 9,763,876, Application No. 14/527,613, 876 FH, filed 29 January 2019 as EX1002 in IPR2019-00451, IPR2019-00450, IPR2019-00449, Part 1 - pp. 1-270.	☐
20	File History for US 9,763,876, Application No. 14/527,613, 876 FH, filed 29 January 2019 as EX1002 in IPR2019-00451, IPR2019-00450, IPR2019-00449, Part 2 - pp. 271-530.	☐
21	Final Office Action mailed 02 November 2018 for U.S. Application No. 15/470,498, 9 pages.	☐
22	Final Office Action mailed 05 May 2020 for U.S. Application No. 15/470,498, 14 pages.	☐

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		18782666
Filing Date		2024-07-24
First Named Inventor	Steve CARTT	
Art Unit		
Examiner Name	Not Yet Assigned	
Attorney Docket Number	148570-014311	

23	Final Office Action mailed 09 April 2021 for U.S. Application No. 16/594,897, 23 Pages.	☐
24	Final Office Action mailed 10 April 2013 for U.S. Application No. 13/371,274, 16 Pages.	☐
25	Final Office Action mailed 10 April 2019 for U.S. Application No. 14/948,081, 22 pages.	☐
26	Final Office Action mailed 10 July 2012 for U.S. Application No. 12/266,529, 16 Pages.	☐
27	Final Office Action mailed 13 March 2015 for U.S. Application No. 12/413,439, 6 pages.	☐
28	Final Office Action mailed 14 July 2016 for U.S. Application No. 12/413,439, 9 Pages.	☐
29	Final Office Action mailed 15 November 2011 for U.S. Application No. 12/116,842, 15 Pages.	☐
30	Final Office Action mailed 17 December 2013 for U.S. Application No. 12/116,842, 26 Pages.	☐
31	Final Office Action mailed 19 October 2017 for U.S. Application No. 12/413,439, 10 pages.	☐
32	Final Office Action mailed 20 June 2017 for U.S. Application No. 14/948,041, 42 Pages.	☐
33	Final Office Action mailed 20 June 2017 for U.S. Application No. 14/948,081, 19 pages.	☐

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	18782666
Filing Date	2024-07-24
First Named Inventor	Steve CARTT
Art Unit	
Examiner Name	Not Yet Assigned
Attorney Docket Number	148570-014311

34	Final Office Action mailed 20 March 2020 for U.S. Application No. 15/955,397, 10 Pages.	☐
35	Final Office Action mailed 21 April 2017 for U.S. Application No. 14/527,613, 7 pages.	☐
36	Final Office Action mailed 21 November 2011 for U.S. Application No. 12/413,439, 9 pages.	☐
37	Final Office Action mailed 25 August 2015 for U.S. Application No. 14/152,686, 16 Pages.	☐
38	FIX "Oral Controlled Release Technology for Peptides: Status and Future prospects" December 1996, Pharmaceutical Research 13(12):1760-1764.	☐
39	Florida Regional Common EMS Protocols Field Guide, Jones and Barlett Publishers, MA, 2005, [filed as EX1069 in IPR2019-00451], 134 Pages.	☐
40	FOOD AND DRUG ADMINISTRATION "Applications Covered by Section 505(b)(2)" 1999, Guidance For Industry retrieved from the internet: https://www.fda.gov/media/72419/download 15 Pages, [filed as EX1148 in IPR2019-00451].	☐
41	FOOD AND DRUG ADMINISTRATION "Determining Whether to Submit an ANDA or a 505(b)(2) Application" Published May 2019, Guidance for Industry FINAL 17 Pages, Retrieved from URL: https://www.fda.gov/media/123567/download [filed as EX1146 in IPR2019-00451].	☐
42	FOOD AND DRUG ADMINISTRATION "Grant Fast Track, IND 112621; NRL-1 (Diazepam Intranasal Solution)" December 27, 2016, 3 Pages, [filed as EX2002 in IPR2019-00451, IPR2019-00450, IPR2019-00449].	☐
43	FRENCH et al. "Initial Management of Epilepsy" July 10, 2008, The New England J. of Medicine 359:166-176, filed as EX2019 in IPR2019-00451.	☐
44	FRENCH et al. "Pharmacopeial Standards and Specifications for Bulk Drugs and Solid Oral Dosage Forms" December 1967, J. Pharmaceutical Sciences 56(12):1622-1641, [filed as EX1033 in IPR2019-00451, IPR2019-00450, IPR2019-00449].	☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666
	Filing Date		2024-07-24
	First Named Inventor	Steve CARTT	
	Art Unit		
	Examiner Name	Not Yet Assigned	
	Attorney Docket Number		148570-014311

45	FRICKER G., et al., "Permeation Enhancement of Octreotide by Specific Bile Salts in Rats and Human Subjects: In Vitro, in Vivo Correlations," British Journal of Pharmacology, January 1996, Vol. 117, No. 1, pp. 217-223.	☐
46	GIZURARSON et al. "Intranasal Administration of Diazepam Aiming at the Treatment of Acute Seizures: Clinical Trials in Healthy Volunteers" April 1999, Biological and Pharmaceutical Bulletin 22(4):425-427 [filed as EX1030 in IPR2019-00451, IPR2019-00450, IPR2019-00449].	☐
47	GORDON et al. "Nasal Absorption of Insulin: Enhancement by Hydrophobic Bile Salts" November 1985, Proceedings of the National Academy of Sciences of the United States of America 82:7419-7423.	☐
48	GREENBLATT et al. "Pharmacokinetics and Pharmacodynamics of Single-Dose Triazolam: Electroencephalography Compared with the Digital-Symbol Substitution Test" 2005, British J. Clinical Pharmacology 60:244-248, [filed as EX1135 in IPR2019-00451].	☐
49	GUDMUNDSDOTTIR et al. "Intranasal Administration of Midazolam in a Cyclodextrin Based Formulation: Bioavailability and Clinical Evaluation in Humans" 2001, Pharmazie 56(12):963-966,[filed as EX1127 in IPR2019-00451].	☐
50	"Handbook of Pharmaceutical Excipients Fifth Ed." 2006, Pharmaceutical Press and American Pharmacists Association, Publishers 12 Pages, [filed as EX2029 in IPR2019-00451].	☐

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666
	Filing Date		2024-07-24
	First Named Inventor	Steve CARTT	
	Art Unit		
	Examiner Name	Not Yet Assigned	
	Attorney Docket Number		148570-014311

CERTIFICATION STATEMENT

Please see 37 CFR 1.97(e) to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☒ A certification statement is not submitted herewith.

FEE

☐ The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

COPIES

☒ An identification of an earlier application pursuant to 37 CFR 1.98 (d) (1) is attached.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/N. Nicole Endejann/	Date (YYYY-MM-DD)	2024-08-30
Name/Print	N. Nicole Endejann	Registration Number	50,229

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666
	Filing Date		2024-07-24
	First Named Inventor	Steve CARTT	
	Art Unit		
	Examiner Name	Not Yet Assigned	
	Attorney Docket Number		148570-014311

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							☐

If you wish to add additional Foreign Patent Document citation information please click the Add button.

Add

NON-PATENT LITERATURE DOCUMENTS				Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666
	Filing Date		2024-07-24
	First Named Inventor	Steve CARTT	
	Art Unit		
	Examiner Name	Not Yet Assigned	
	Attorney Docket Number		148570-014311

1	HARBORD et al. "Use of Intranasal Midazolam to Treat Acute Seizures in Paediatric Community Settings" 2004, J. of Paediatrics and Child Health 40(9-10):556-558, [filed as EX1142 in IPR2019-00451].	☐
2	HARDMAN et al. "Goodman & Gilman's: The Pharmacological Basis of Therapeutics" 2001, 10th Ed., 6 Pages, [filed as EX1074 in IPR2019-00451].	☐
3	HATHCOX et al. "Inhibitory Effects of Sucrose Fatty Acid Esters, Alone and in Combination with Ethylenediaminetetraacetic Acid and Other Organic Acids, on Viability of Escherichia Coli O157:H7" 1996, Food Microbiology 13:213-225,.	☐
4	HENDELES et al. "Oral Phenylephrine: An Ineffective Replacement For Pseudoephedrine?" July 2006, The J. Allergy and Clinical Immunology 118(1):279-280 (abstract).	☐
5	HOGAN et al. "Pharmacokinetics and Safety of VALTOCO (NRL-1; Diazepam Nasal Spray) in Patients with Epilepsy Luring Seizure (ictal/peri-ictal) and Nonseizure (Interictal) Conditions: A Phase 1, Open-Label Study" April 27, 2020, Epilepsia 61(5):935-943.	☐
6	HOLFORD et al. "Pharmacokinetics and Pharmacodynamics: Dose Selection and the Time Course of Drug Action" 1998, In: KATZUNG B.G., Basic and Clinical Pharmacology 7th edition Appleton and Lange, Stamford, CT 34-49.	☐
7	HOLSTI et al. "Prehospital Intranasal Midazolam for the Treatment of Pediatric Seizures" March 2007, Pediatric Emergency Care 23(3):148-153, [filed as EX1121 in IPR2019-00451].	☐
8	HOVGAARD et al. "Insulin Stabilization and Gastrointestinal Absorption" Dissertation, August 1991, Department of Pharmaceutics, The University of Utah 255 Pages.	☐
9	HOVGAARD et al. "Insulin Stabilization and GI Absorption" March 1992, J. Controlled Release 19(1-3):99-108.	☐
10	HOVGAARD et al. "Stabilization of Insulin by Alkylmaltosides. A. Spectroscopic Evaluation" 1996, International J. of Pharmaceutics 132:107-113.	☐
11	HOVGAARD et al. "Stabilization of Insulin by Alkylmaltosides. B. Oral Absorption In Vivo In Rats" 1996, International J. of Pharmaceutics 132:115-121.	☐

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	18782666
Filing Date	2024-07-24
First Named Inventor	Steve CARTT
Art Unit	
Examiner Name	Not Yet Assigned
Attorney Docket Number	148570-014311

12	"How Does the Nose Work? The Nasal Mucosa" retrieved from the internet: https://www.fitonasal2act.com/how-does-the-nose-work/the-nasal-mucosa/ (November 05, 2019), 2 Pages, [filed as EX2021 in IPR2019-00451].	☐
13	HUSSAIN et al. "Absorption Enhancers in Pulmonary Protein Delivery" 2004, J. Controlled Release 94:15-24.	☐
14	HUSSAIN et al. "Nasal Absorption of Propranolol in Humans" October 1980, J. of Pharmaceutical Sciences 69(10):1 Page, filed as EX2008 in IPR2019-00451].	☐
15	ILLUM "Is Nose to Brain Transport of Drugs a Reality?" 2004, J. Pharmacy and Pharmacology 56: 3-17, [filed as EX1116 in IPR2019-00451].	☐
16	ILLUM "Nasal Clearance in Health and Disease" 2006, J. Aerosol Medicine 19(1): 92-99, [filed as EX1113 in IPR2019-00451].	☐
17	ILLUM "Nasal Drug Delivery-Possibilities, Problems and Solutions" 2003, J. Controlled Release 87:187-198, [filed as EX1027 in IPR2019-00451, IPR2019-00450, IPR2019-00449].	☐
18	ILLUM "Nasal Drug Delivery-Recent Developments and Future Prospects" 2012, J. Controlled Release 161 (2):254-263.	☐
19	ILLUM "Transport of Drugs from the Nasal Cavity to the Central Nervous System" 2000, European J. of Pharmaceutical Sciences 11:19 Pages, [filed as EX1115 in IPR2019-00451].	☐
20	International Preliminary Report on Patentability for PCT/US2009/038696, dated September 28, 2010, 06 Pages.	☐
21	International Search Report and Written Opinion for PCT/US2008/062961 dated August 04, 2008, 9 Pages.	☐
22	International Search Report and Written Opinion for PCT/US2009/038696, dated September 28, 2009, 09 Pages.	☐

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	18782666
Filing Date	2024-07-24
First Named Inventor	Steve CARTT
Art Unit	
Examiner Name	Not Yet Assigned
Attorney Docket Number	148570-014311

23	International Search Report and Written Opinion for PCT/US2011/056735 dated June 20, 2012, 8 Pages.	☐
24	International Search Report and Written Opinion for PCT/US2012/042311 dated August 31, 2012, 10 Pages.	☐
25	International Search Report and Written Opinion for PCT/US2014/070944 dated April 15, 2015, 11 Pages.	☐
26	International Search Report and Written Opinion for PCT/US2022/011538 dated March 30, 2022, 14 Pages.	☐
27	"Intranasal Technology, Incorporated Licenses Aegis Therapeutics Intravital Drug Delivery Technology" Business Wire, April 13, 2005, 02 Pages, [filed as EX2028 in IPR2019-00451].	☐
28	IVATURI et al. "Pharmacokinetics and Tolerability of Intranasal Diazepam and Midazolam in Healthy Adult Volunteers" November 2009, Acta Neurologica Scandinavica 120(5):353-357, (Epub. May 14, 2009), doi: 10.1111/j.1600-0404.2009.01170.x, [filed as EX1028 in IPR2019-00451, IPR2019-00450, IPR2019-00449].	☐
29	Japan Decision of Refusal for Japanese Application No. 2010-507633, mailed July 09, 2013, 4 Pages.	☒
30	Japan Office Action for Japanese Application No. 2010-507633, mailed October 23, 2012, 10 Pages.	☒
31	Japan Office Action for Japanese Application No. 2014-515967, mailed April 24, 2017, 4 Pages.	☒
32	Japan Office Action for Japanese Application No. 2014-515967, mailed March 30, 2016, 10 Pages.	☒
33	Japan Office Action for Japanese Application No. 2014-515967, mailed November 28, 2016, 8 Pages.	☒

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	18782666
Filing Date	2024-07-24
First Named Inventor	Steve CARTT
Art Unit	
Examiner Name	Not Yet Assigned
Attorney Docket Number	148570-014311

34	Japan Office Action for Japanese Application No. 2017-185485, mailed July 02, 2018, 7 Pages.	☒
35	Japan Office Action for Japanese Application No. 2019-083274, mailed March 25, 2020, 13 Pages.	☒
36	Japan Office Action for Japanese Application No. 2019-083274, mailed November 18, 2020, 11 Pages.	☒
37	JEANNET et al. "Home and Hospital Treatment of Acute Seizures in Children with Nasal Midazolam" 1999, European J. Paediatric Neurology 3(2):73-77, [filed as EX1143 in IPR2019-00451].	☐
38	Judgment Final Written Decision of U.S. Patent No. 9,763,876, filed 06 August 2020 in IPR2019-00451, 70 Pages.	☐
39	KIBBE, "Handbook of Pharmaceutical Excipients Third Ed." 2000, American Pharmaceutical Association, Washington, DC. (12 pages).	☐
40	KISSEL et al. "Tolerability and Absorption Enhancement of Intranasally Administered Octreotide by Sodium Taurodihydrofusidate in Healthy Subjects" January 1992, Pharmaceutical Research 9(1):52-57.	☐
41	KITE et al. "Use of in Vivo-Generated Biofilms from Hemodialysis Catheters to Test the Efficacy of a Novel Antimicrobial Catheter Lock for Biofilm Eradication in Vitro" July 2004, J. Clinical Microbiology 42(7):3073-3076.	☐
42	KNOESTER et al. "Pharmacokinetics And Pharmacodynamics Of Midazolam Administered As A Concentrated Intranasal Spray: A Study In Healthy Volunteers" 2002, British J. Clinical Pharmacology 53:501-507.	☐
43	KNUDSEN "Glucagon-Like Peptide-1: The Basis of a New Class of Treatment for Type 2 Diabetes" 2004, J. Medicinal Chemistry 47(17):4128-4134.	☐
44	LACY et al. "Drug Information Handbook, 7th Ed. 1999-2000" 1999, Lexi-Comp Incorporated 163-164.	☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666
	Filing Date		2024-07-24
	First Named Inventor	Steve CARTT	
	Art Unit		
	Examiner Name	Not Yet Assigned	
	Attorney Docket Number		148570-014311

45	LAHAT et al. "Comparison of Intranasal Midazolam with Intravenous Diazepam in Treating Febrile Seizures in Children: Prospective Randomized Study" 2000, British Medical J. 321:6 Pages, [filed as EX1139 in IPR2019-00451].	☐
46	LAHAT et al. "Intranasal Midazolam for Childhood Seizures" August 22, 1998, The Lancet 352(9128):620(1 Page).	☐
47	LAU et al. "Absorption Of Diazepam And Lorazepam Following Intranasal Administration" 1989, International J. Pharmaceutics 54:171-174, [filed as EX2009 in IPR2019-00451].	☐
48	LEHNINGER et al. "Principles of Biochemistry with an Extended Discussion of Oxygen-Binding Proteins Second Edition" 1982, 1993 Worth Publishers, New York, NY 150-151.	☐
49	LEWINE "Quick Injection Helps Stop Epileptic Seizures, Harvard Health Blog" February 23, 2012, filed as EX2003 in IPR2019-00451, IPR2019-00450, IPR2019-00449, Retrieved from the Internet: https://www.health.harvard.edu/blog/quick-injection-helps-stop-epileptic-seizures-201202234319/print/ . 1 Page.	☐
50	LINDHARDT et al. "Electroencephalographic Effects and Serum Concentrations After Intranasal and Intravenous Administration of Diazepam to Healthy Volunteers" 2001, Blackwell Science Ltd, British J. Clinical Pharmacology 52:521-527, [Filed as EX1025 in IPR2019-00451, IPR2019-00450, IPR2019-00449].	☐

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666
	Filing Date		2024-07-24
	First Named Inventor	Steve CARTT	
	Art Unit		
	Examiner Name	Not Yet Assigned	
	Attorney Docket Number	148570-014311	

CERTIFICATION STATEMENT

Please see 37 CFR 1.97(e) to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☒ A certification statement is not submitted herewith.

FEE

☐ The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

COPIES

☒ An identification of an earlier application pursuant to 37 CFR 1.98 (d) (1) is attached.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/N. Nicole Endejann/	Date (YYYY-MM-DD)	2024-08-30
Name/Print	N. Nicole Endejann	Registration Number	50,229

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666	
	Filing Date		2024-07-24	
	First Named Inventor	Steve CARTT		
	Art Unit			
	Examiner Name	Not Yet Assigned		
	Attorney Docket Number		148570-014311	

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS									Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵	
	1	2006055603	WO	A2	2006-05-26	ELAN PHARMA INT LTD, et al.		☐	
	2	2006075123	WO	A1	2006-07-20	CAMURUS AB, et al.		☐	
	3	2006088894	WO	A2	2006-08-24	ELAN PHARMA INT LTD, et al.		☐	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666	
	Filing Date		2024-07-24	
	First Named Inventor	Steve CARTT		
	Art Unit			
	Examiner Name	Not Yet Assigned		
	Attorney Docket Number		148570-014311	

	4	2007043057	WO	A2	2007-04-19	YISSUM RES DEV CO, et al.		☐
	5	2007144081	WO	A2	2007-12-21	LOHMANN THERAPIE SYST LTS, et al.	with English Abstract	☒
	6	2008027395	WO	A2	2008-03-06	JAZZ PHARMACEUTICALS, et al.		☐
	7	2008120207	WO	A2	2008-10-09	YISSUM RES DEV CO, et al.		☐
	8	2008137960	WO	A1	2008-11-13	QUESTOR PHARMACEUTICALS INC, et al.		☐
	9	2009120933	WO	A2	2009-10-01	PARTICLE SCIENCES INC, et al.		☐
	10	2009121039	WO	A2	2009-10-01	HALE BIOPHARMA VENTURES LLC, et al.		☐
	11	2012174058	WO	A1	2012-12-20	CROWN PACKAGING TECHNOLOGY INC, et al.		☐
	12	2012174158	WO	A2	2012-12-20	HALE BIOPHARMA VENTURES LLC, et al.		☐

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
-----------------------	------------	---	----------------

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	18782666
Filing Date	2024-07-24
First Named Inventor	Steve CARTT
Art Unit	
Examiner Name	Not Yet Assigned
Attorney Docket Number	148570-014311

1	COSTANTINO et al. "Intranasal Delivery: Physicochemical and Therapeutic Aspects" 2007, International J. Pharmaceutics 337:1-24, [filed as EX1118 in IPR2019-00451].	☐
2	DALE et al. "Intranasal Midazolam: a Comparison of Two Delivery Devices in Human Volunteers" 2006, J . Pharmacy and Pharmacology 58:1311-1318, [filed as EX1128 in IPR2019- 00451].	☐
3	DANIEL P. WERMELING Deposition Transcript, 26 February 2020, 150 Pages, [filed as EX2031 in IPR2019-00451].	☐
4	DAVIS "Delivery Of Peptide and Non-Peptide Drugs through the Respiratory Tract" November 1999, Pharmaceutical Science & Technology Today 2(11):450-456, [filed as EX1035 in IPR2019-00451, IPR2019-00450, IPR2019-00449].	☐
5	DAVIS et al. "Absorption Enhancers for Nasal Drug Delivery" 2003, Clinical Pharmacokinetics 42(13):1107-1128.	☐
6	DAVIS et al. "Bioavailability and Pharmacokinetics of Intranasal Hydromorphone in Patients Experiencing Vasomotor Rhinitis" 2004, Clin. Drug Invest. 24(11):633-639, [Filed as EX1120 in IPR2019-00451].	☐
7	DAVIS et al. "Effect of Fluticasone Propionate Nasal Spray on Bioavailability of Intranasal Hydromorphone Hydrochloride in Patients With Allergic Rhinitis" 2004, Pharmacotherapy 24(1)26-32, [Filed as EX1119 in IPR2019-00451].	☐
8	DE VRY et al. "Effects of Selected Serotonin 5-HT(1) and 5-HT(2) Receptor Agonists on Feeding Behavior: Possible Mechanisms of Action" 2000, Neuroscience and Biobehavioral Reviews 24(3):341-353.	☐
9	Decision Denying Institution of Inter Partes Review of U.S. Patent No. 9,763,876, filed 01 August 2019 in IPR2019-00449, 27 Pages.	☐
10	Decision Denying Institution of Inter Partes Review of U.S. Patent No. 9,763,876, filed 01 August 2019 in IPR2019-00450, 23 Pages.	☐
11	Decision Denying Patent Owner's Request on Rehearing of Decision on Institution of U.S. Patent No. 9,763,876, filed 27 September 2019 in IPR2019-00451, 7 Pages.	☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	18782666
	Filing Date	2024-07-24
	First Named Inventor	Steve CARTT
	Art Unit	
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	148570-014311

12	Decision Denying Petitioner's Request for Rehearing of Decision Denying Institution of Inter Partes Review of U.S. Patent No. 9,763,876, filed 27 September 2019 in IPR2019-00449, 8 Pages.	☐
13	Decision Instituting Inter Partes Review of U.S. Patent No. 9,763,876, filed 13 August 2019 in IPR2019-00451, 42 Pages.	☐
14	Declaration of Daniel P. Wermeling, Pharm.D., Executed 27 January 2020, [filed as EX1150 in IPR2019-00451], 175 Pages.	☐
15	Declaration of Dr. Nicholas A. Peppas, Executed 06 December 2018, [filed as EX1041 in IPR2019-00449], 420 Pages.	☐
16	Declaration of Dr. Nicholas A. Peppas, Executed 06 December 2018, [filed as EX1041 in IPR2019-00450], 459 Pages.	☐
17	Declaration of Dr. Nicholas A. Peppas, Executed 06 December 2018, [filed as EX1041 in IPR2019-00451], 459 Pages.	☐
18	Declaration of Dr. Sveinbjorn Gizurason, Ph.D., Executed 04 November 2019, [filed as EX2012 in IPR2019-00451], 113 Pages.	☐
19	Declaration of Michael I. Chakansky Executed 19 February 2020, [filed as EX1152 in IPR2019-00451], 7 Pages.	☐
20	"Definition of Enkephalin" retrieved from the internet: http://medical-dictionary.thefreedictionary.com/p/enkephalin (September 13, 2012) 1 Page.	☐
21	"Definition of Pilus" Merriam-Webster Medical Dictionary, retrieved from the internet: http://www.merriam-webster.com/medical/pilus (May 28, 2013).	☐
22	"Definition of Villus" Merriam-Webster Medical Dictionary, retrieved from the URL: http://www.merriam-webster.com/medical/villus (May 28, 2013) 2 Pages.	☐

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	18782666
Filing Date	2024-07-24
First Named Inventor	Steve CARTT
Art Unit	
Examiner Name	Not Yet Assigned
Attorney Docket Number	148570-014311

23	DESHMUKH et al. "Lorazepam in the Treatment of Refractory Neonatal Seizures" October 1986, The American J. Diseases of Children 140(10):1042-1044, [filed as EX1036 in IPR2019-00451, IPR2019-00450, IPR2019-00449].	☐
24	DIASTAT Label, 2005, [filed as EX2017 in IPR2019-00451], 2 Pages.	☐
25	Dr. Nicholas Peppas Deposition Transcript, October 24, 2019, 158 Pages, [filed as EX2011 in IPR2019-00451].	☐
26	DREWE et al. "Enteral Absorption of Octreotide: Absorption Enhancement by Polyoxyethylene-24-cholesterol Ether" 1993, British J. Pharmacology 108(2):298-303.	☐
27	Drug Prices from Internet, Accessed January 24, 2020, 6 Pages, [filed as EX1081 in IPR2019-00451].	☐
28	DUQUESNOY et al. "Comparative Clinical Pharmacokinetics of Single Doses of Sumatriptan Following Subcutaneous, Oral, Rectal and Intranasal Administration" 1998, European J. Pharmaceutical Sciences 6(2):99-104.	☐
29	EDMAN et al. "(D) Routes of Delivery: Case Studies - (1) Nasal Delivery of Peptide Drugs" 1992, Advanced Drug Delivery Reviews 8:165-177, [filed as EX1034 in IPR2019-00451, IPR2019-00450, IPR2019-00449].	☐
30	EDMAN et al. "Microspheres as a Nasal Delivery System for Peptide Drugs" 1992, J. Controlled Release, 21 (1992):165-172 [filed as EX1032 in IPR2019-00451, IPR2019-00450, IPR2019- 00449].	☐
31	ELEY et al. "In Vitro Assessment of Alkylglycosides as Permeability Enhancers" 2001, AAPS PharmSciTech, 2(3):1-7.	☐
32	Email Sent 30 September 2019 Requesting Precedential Opinion Panel Review, [filed as EX3001 in IPR2019-00451], 3 Pages.	☐
33	Epilepsy Fast Facts, Center for Disease Control and Preventions, CDC 24/7, Saving Lives, Protection People, 09 April 2019, pp. 1-2, [filed as EX2001 in IPR2019-00451, IPR2019-00450, PR2019-00449], Retrieved from URL: https://www.cdc.gov/epilepsy/about/fast-facts.htm?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fepilepsy%2Fbasics%2Ffast-facts.html .	☐

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	18782666
Filing Date	2024-07-24
First Named Inventor	Steve CARTT
Art Unit	
Examiner Name	Not Yet Assigned
Attorney Docket Number	148570-014311

34	ERIKSSON et al. "Pharmacologic Management of Convulsive Status Epilepticus in Childhood" 2005, Expert Rev Neurotherapeutics 5(6):777-783, [Filed as EX1109 in IPR2019-00451].	☐
35	European Communication Pursuant to Article 94(3) EPC for European Application No. 12801372.9, mailed 05 July 2016, 7 pages.	☐
36	European Office Action for European Application No. 08747813.7 mailed June 24, 2011, 5 Pages.	☐
37	European Office Action for European Application No. 18171484.1 mailed April 06, 2020, 8 Pages.	☒
38	European Office Action for European Application No. 18171484.1, mailed May 17, 2021, 7 Pages.	☐
39	European Search Report and Written Opinion for EP 08747813.7 received June 22, 2010, 08 Pages.	☐
40	European Search Report and Written Opinion for EP 09723906.5 received June 03, 2013, 5 Pages.	☐
41	European Search Report and Written Opinion for EP 09835809.6 received November 13, 2012, 8 Pages.	☐
42	European Search Report and Written Opinion for EP 11835002.4 received July 07, 2015, 6 Pages.	☐
43	European Search Report and Written Opinion for EP 12801372.9 received March 26, 2015, 09 Pages.	☐
44	European Search Report and Written Opinion for EP 18171484.1 received October 30, 2018, 13 Pages.	☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666
	Filing Date		2024-07-24
	First Named Inventor	Steve CARTT	
	Art Unit		
	Examiner Name	Not Yet Assigned	
	Attorney Docket Number		148570-014311

45	European Summons to Attend Oral Proceedings with Annex for EP 12801372.9 dated 16 May 2017, 8 Pages.	☐
46	FEEN et al. "Status Epilepticus" 2008, Southern Medical Journal 101:400-406, [Filed as EX1106 in PR2019-00451].	☐
47	FETIH et al. "Improvement of Absorption Enhancing Effects of N-Dodecyl-Beta-D-Maltopyranoside by Its Colon-Specific Delivery Using Chitosan Capsules" 2005, International J. Pharmaceutics 293:127-135.	☐
48	FIEST et al. "Prevalence and Incidence of Epilepsy, A Systematic Review and Meta-Analysis of International Studies" January 17, 2017, Neurology 88:296-303, [filed as EX2005 in IPR2019-00451, IPR2019-00450, PR2019-00449].	☐
49	File History for EP 12801372.9, Based on WO2012/174158 and PCT/US2012/042311, filed 29 January 2019 as EX1040 in IPR2019-00451, IPR2019-00450, IPR2019-00449, Part 1 - pp. 1-250.	☐
50	File History for EP 12801372.9, Based on WO2012/174158 and PCT/US2012/042311, filed 29 January 2019 as EX1040 in IPR2019-00451, IPR2019-00450, IPR2019-00449, Part 2 - pp. 251-500.	☐

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666
	Filing Date		2024-07-24
	First Named Inventor	Steve CARTT	
	Art Unit		
	Examiner Name	Not Yet Assigned	
	Attorney Docket Number	148570-014311	

CERTIFICATION STATEMENT

Please see 37 CFR 1.97(e) to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☒ A certification statement is not submitted herewith.

FEE

☐ The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

COPIES

☒ An identification of an earlier application pursuant to 37 CFR 1.98 (d) (1) is attached.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/N. Nicole Endejann/	Date (YYYY-MM-DD)	2024-08-30
Name/Print	N. Nicole Endejann	Registration Number	50,229

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666
	Filing Date		2024-07-24
	First Named Inventor	Steve CARTT	
	Art Unit		
	Examiner Name	Not Yet Assigned	
	Attorney Docket Number	148570-014311	

U.S.PATENTS							Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Patent citation information please click the Add button.							Add	
U.S.PATENT APPLICATION PUBLICATIONS							Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Published Application citation information please click the Add button.							Add	
FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							☐
If you wish to add additional Foreign Patent Document citation information please click the Add button								Add
NON-PATENT LITERATURE DOCUMENTS								Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		18782666
Filing Date		2024-07-24
First Named Inventor	Steve CARTT	
Art Unit		
Examiner Name	Not Yet Assigned	
Attorney Docket Number		148570-014311

1	OGISO et al. "Percutaneous Absorption of Elcatonin and Hypocalcemic Effect in Rat" February 1991, Chemical & Pharmaceutical Bulletin, The Pharmaceutical Society of Japan, Tokyo, Japan 39(2):449-453.	☐
2	OLESEN et al. "The Headaches" October 11, 2005, Lippincott Williams & Wilkins, XP002684971.	☐
3	Order Denying POP Request, filed 15 November 2019 in IPR2019-00451, 3 Pages.	☐
4	O'REGAN et al. "Nasal Rather than Rectal Benzodiazepines in the Management of Acute Childhood Seizures?" 1996, Developmental Medicine & Child Neurology 38:1037-1045, [filed as EX1136 in IPR2019-00451].	☐
5	OSBORNE et al. "Skin Penetration Enhancers Cited In The Technical Literature" November 1997, Pharmaceutical Technology, 35 Pages, (filed as EX1024 in IPR2019-00451, IPR2019-00450, IPR2019-00449).	☐
6	PANG et al. "Treatment of Convulsive and Nonconvulsive Status Epilepticus" 2005, Current Treatment Options in Neurology 7:247-259 [filed as EX1107 in IPR2019-00451].	☐
7	Parties' Joint Submission of Patent Owner's Identification of New Arguments and Petitioner's Responses Thereto filed 25 February 2020 in IPR2019-00451, 10 Pages.	☐
8	Patent Owner's Notice of Appeal filed 08 October 2020 in IPR2019-00451, 5 Pages.	☐
9	Patent Owner's Preliminary Response, filed 06 May 2019 in IPR2019-00449, 30 Pages.	☐
10	Patent Owner's Preliminary Response, filed 06 May 2019 in IPR2019-00450, 30 Pages.	☐
11	Patent Owner's Preliminary Response, filed 21 May 2019 in IPR2019-00451, 35 Pages.	☐

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	18782666
Filing Date	2024-07-24
First Named Inventor	Steve CARTT
Art Unit	
Examiner Name	Not Yet Assigned
Attorney Docket Number	148570-014311

12	Patent Owner's Request for Rehearing of U.S. Patent No. 9,763,876, filed 27 August 2019 in IPR2019-00451, 17 Pages.	☐
13	Patent Owner's Response to the Petition, filed 05 November 2019 in IPR2019-00451, 54 Pages.	☐
14	Patent Owner's Surreply to Patent Owner's Response, filed 10 March 2020 in IPR2019-00451, 34 Pages.	☐
15	PAULSSON "Controlled Drug Release from Gels Using Surfactant Aggregates. II. Vesicles formed from Mixtures of Amphiphilic Drugs and Oppositely Charged Surfactants" November 2001, Pharmaceutical Research, 18 (11):1586-1592.	☐
16	PDR 54th Edition 2000, Diastat (Diazepam rectal gel), Miacalcin (Calcitonin Nasal Spray), Valium (Diazepam injection), Physicians' Desk Reference, [filed as EX1042 in IPR2019-00451, IPR2019-00450, IPR2019-00449], 15 Pages.	☐
17	Petition for Inter Partes Review for U.S. Patent No. 9,763,876 (IPR2019-00449) dated January 28, 2019, 103 Pages.	☐
18	Petition for Inter Partes Review for U.S. Patent No. 9,763,876 (IPR2019-00450) dated January 29, 2019, 109 Pages.	☐
19	Petition for Inter Partes Review for U.S. Patent No. 9,763,876 (IPR2019-00451) dated January 29, 2019, 107 Pages.	☐
20	Petitioner's Reply to Patent Owner's Response to the Petition of U.S. Patent No. 9,763,876, filed 28 January 2020 in IPR2019-00451, 38 Pages.	☐
21	Petitioner's Request for Rehearing Pursuant to 37 C.F.R. 42.71(d) of U.S. Patent No. 9,763,876, filed 03 September 2019 in IPR2019-00449, 19 Pages.	☐
22	PHILLIPS "The Challenge of Gene Therapy and DNA Delivery" 2001, J. Pharmacy and Pharmacology 53:1169-1174.	☐

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	18782666
Filing Date	2024-07-24
First Named Inventor	Steve CARTT
Art Unit	
Examiner Name	Not Yet Assigned
Attorney Docket Number	148570-014311

23	PILLION et al. "Synthetic Long-chain Alkyl Maltosides and Alkyl Sucrose Esters as Enhancers of Nasal Insulin Absorption" June 2002, J. Pharmaceutical Sciences 91(6):1456-1462.	☐
24	PILLION et al. "Systemic Absorption Of Insulin Delivered Topically To The Rat Eye" November 1991, Investigative Ophthalmology & Visual Science 32(12):3021-3027.	☐
25	PIROLLO et al. "Targeted Delivery of Small Interfering RNA: Approaching Effective Cancer Therapies" 2008, Cancer Research 68(5):1247-1250.	☐
26	PRASAD et al. "Anticonvulsant Therapy For Status Epilepticus" 2007, British J . Clinical Pharmacology 63(6):640-647 [filed as EX1112 in IPR2019-00451].	☐
27	Record of Oral Hearing held 14 May 2020, filed 27 May 2020 in IPR2019-00451, 60 Pages.	☐
28	RICHARDS "Inactivation of Resistant Pseudomonas Aeruginosa By Antibacterial Combinations" January 18, 1971, J. Pharmacy and Pharmacology 23:136S-140S.	☐
29	RISS et al. "Benzodiazepines In Epilepsy: Pharmacology and Pharmacokinetics" 2008, Acta Neurologica Scandinavica 118:69-86 [filed as EX2013 in IPR2019-00451].	☐
30	RITSCHER et al. "Handbook of Basic Pharmacokinetics Including Clinical Applications" 2004, 6th Edition 1-8 [filed as EX1077 in IPR2019-00451].	☐
31	RITSCHER "Handbook of Basic Pharmacokinetics Including Clinical Applications" 1992, Chapter 36 (Bioavailability and Bioequivalence) Illinois 1-36 [filed as EX1023 in IPR2019- 00451, IPR2019-00450, IPR2019-00449].	☐
32	ROWE et al. "Handbook of Pharmaceutical Excipients" 2003, Fourth Edition Monographs American Pharmaceutical Association Washington DC 13-15, 27-29, 53-55, 257-259, 414-416, 454-459, 521-523, 535-537, 659-660, [filed as EX1031 in IPR2019-00451, IPR2019-00450, IPR2019-00449].	☐
33	RUDY et al. "A Multiple-Dose Phase 1 Study of Intranasal Hydromorphone Hydrochloride in Healthy Volunteers" 2004, Anesthesia Analgesia 99:1379-1386, [filed as EX1122 in IPR2019-00451].	☐

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	18782666
Filing Date	2024-07-24
First Named Inventor	Steve CARTT
Art Unit	
Examiner Name	Not Yet Assigned
Attorney Docket Number	148570-014311

34	Rule 36 Judgment entered 7 October 2021, U.S. Court of Appeals for the Federal Circuit, Neurelis, Inc., Appellant v. Aquestive Therapeutics, Inc., Appellee, Appeal No. 2021-1038, affirming decision in IPR2019-00451, 2 Pages, (U.S. Pat. No. 9,763,876).	☐
35	SALEM et al. "Approaches to the Pharmacological Treatment of Obesity" Expert Review of Clinical Pharmacology, February 5, 2010, retrieved from the internet: http://www.medscape.com/viewarticle/714793_print 3(1):73-88.	☐
36	SALZMAN et al. "Intranasal Aerosolized Insulin" April 1985, The New England J. Medicine, 312(17):1078-1084.	☐
37	SANDERS et al. "Pharmacokinetics of Ergotamine in Healthy Volunteers Following Oral and Rectal Dosing" 1989, European J. Clinical Pharmacology, 30(3):331-334.	☐
38	SCHMIDT "New Methods for the Synthesis of Glycosides and Oligosaccharides: Are There Alternatives to the Koenigs-Knorr Method?" 1986, Angewandte Chemie International edition in English 25(3):212-235.	☐
39	SCHOLS-HENDRIKS et al. "Absorption of Clonazepam After Intranasal and Buccal Administration" 1995, British Journal of Clinical Pharmacology, 39:449-451, [filed as EX2010 in IPR2019-00451].	☐
40	SENEL et al. "Drug Permeation Enhancement Via Buccal Route: Possibilities and Limitations" 2001, J. Controlled Release 72:133-144.	☐
41	SHIM et al. "Administration Route Dependent Bioavailability of Interferon- α and Effect of Bile Salts on the Nasal Absorption" 1993, Drug Development and Industrial Pharmacy 19(10):1183-1199.	☐
42	SIGMA Chemical Company Catalog, 1988, [filed as EX2006 in IPR2019-00451], 33 Pages.	☐
43	SMITH "Treatment of Status Epilepticus" May 2001, Neurologic Clinics 19(2):347-369, [filed as EX1108 in IPR2019-00451].	☐
44	STAVEM et al. "Long-Term Seizures and Quality of Life After Epilepsy Surgery Compared with Matched Controls" 2008, Neurosurgery 62:326-334, [filed as EX1104 in IPR2019-00451].	☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666
	Filing Date		2024-07-24
	First Named Inventor	Steve CARTT	
	Art Unit		
	Examiner Name	Not Yet Assigned	
	Attorney Docket Number		148570-014311

45	STEVENS et al. "Use of Glucagon to Treat Neonatal Low-Output Congestive Heart Failure after Maternal Labetalol Therapy" July 1995, J. Pediatrics 127(1): 151-153.	☐
46	SUN et al. "Nasal Spray for Curing Status Epilepticus (SE) and Epilepsy, Comprises Alprazolam and Carriers" 2001, DATABASE WPI, 0, Derwent World Patents Index 64:1 Page, Database Accession No. 2001-566115, XP002737233& CN1303674 A 20010718 ((SHAN-N) SHANDONG PROV MEDICAL IND INST).	☐
47	SWARBRICK et al. "Encyclopedia of Pharmaceutical Technology" 2002, Second edition Informa Health Care 1:918.	☐
48	Table of Various Diazepam Solutions Described in or Modified From Sonne's Example 11, filed 29 January 2019, 01 page, [as EX1050 in IPR2019-00451, IPR2019-00450].	☐
49	TERRY et al. "Acceptance of the Use of Diazepam Rectal Gel in School and Day Care Settings" 2007, J. Child Neurology 22:1135-1138(4 Pages), [filed as EX2016 in IPR2019-00451].	☐
50	TILLMAN et al. "Oral Delivery of Antisense Oligonucleotide in Man" August 22, 2007, J. Pharmaceutical Sciences, 97 (1):225-236.	☐

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666
	Filing Date		2024-07-24
	First Named Inventor	Steve CARTT	
	Art Unit		
	Examiner Name	Not Yet Assigned	
	Attorney Docket Number	148570-014311	

CERTIFICATION STATEMENT

Please see 37 CFR 1.97(e) to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☒ A certification statement is not submitted herewith.

FEE

☐ The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

COPIES

☒ An identification of an earlier application pursuant to 37 CFR 1.98 (d) (1) is attached.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/N. Nicole Endejann/	Date (YYYY-MM-DD)	2024-08-30
Name/Print	N. Nicole Endejann	Registration Number	50,229

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666
	Filing Date		2024-07-24
	First Named Inventor	Steve CARTT	
	Art Unit		
	Examiner Name	Not Yet Assigned	
	Attorney Docket Number		148570-014311

U.S.PATENTS							Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Patent citation information please click the Add button.							Add	
U.S.PATENT APPLICATION PUBLICATIONS							Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Published Application citation information please click the Add button.							Add	
FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							☐
If you wish to add additional Foreign Patent Document citation information please click the Add button								Add
NON-PATENT LITERATURE DOCUMENTS								Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						T ⁵

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666
	Filing Date		2024-07-24
	First Named Inventor	Steve CARTT	
	Art Unit		
	Examiner Name	Not Yet Assigned	
	Attorney Docket Number		148570-014311

1	Transcript of Dr. Gizurarson's Deposition on January 14, 2020, [filed as EX1149 in IPR2019-00451], 162 Pages.	☐
2	Transcript of Telephone Conference on February 11, 2020, [filed as EX2027 in IPR2019-00451], 25 Pages.	☐
3	TSUCHIDO et al. "Lysis of Bacillus Subtilis Cells by Glycerol and Sucrose Esters of Fatty Acids," March 1987, Applied and Environmental Microbiology 53(3):505-508.	☐
4	TURKER et al. "Nasal Route and Drug Delivery Systems" 2004, Pharmacy World and Science 26(3):137-142.	☐
5	TURTON et al. "A Role for Glucagon-Like Peptide-1 in the Central Regulation of Feeding" January 4, 1996, Nature 379:69-72.	☐
6	"UCB announces NAYZILAM (Midazolam) Nasal Spray Now Approved By FDA To Treat Intermittent, Stereotypic Episodes Of Frequent Seizure Activity In People Living With Epilepsy In The U.S" May 20, 2019, UCB Press Release, 14 pages, [filed as EX2018 in IPR2019-00451].	☐
7	U.S. Patent Application No. 14/990,645 filed January 7, 2016, 83 Pages.	☐
8	U.S. Provisional Application No. 60/148,464 filed 12 August 1999, 93 Pages.	☐
9	U.S. Provisional Application No. 60/632,038, filed 30 November 2004, 37 Pages, [filed as EX1065 in IPR2019-00451, IPR2019-00450].	☐
10	U.S. Provisional Application No. 61/040,281, filed 28 March 2008, 25 Pages, [filed as EX1046 in IPR2019-00451, IPR2019-00450, IPR2019-00449].	☐
11	U.S. Provisional Application No. 61/040,558, filed 28 March 2008, [filed as EX1008 in IPR2019-00451, IPR2019-00450, IPR2019-00449], 60 Pages.	☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666
	Filing Date		2024-07-24
	First Named Inventor	Steve CARTT	
	Art Unit		
	Examiner Name	Not Yet Assigned	
	Attorney Docket Number		148570-014311

12	U.S. Provisional Application No. 61/497,017, filed 14 June 2011, [filed as EX1005 in IPR2019-00451, IPR2019-00450, IPR2019-00449], 105 Pages.	☐
13	U.S. Provisional Application No. 61/570,110, filed 13 December 2011, [filed as EX1006 in IPR2019-00451, IPR2019-00450, IPR2019-00449], 104 Pages.	☐
14	USP NF: "(1088) In Vitro And In Vivo Evaluation" 2003, The United States Pharmacopeia, The National Formulary, United States Pharmacopeial Convention Incorporated 2334-2339 Pages, [filed as EX1044 in IPR2019-00451, IPR2019-00450, IPR2019-00449].	☐
15	USP NF: "The Official Compendia of Standards" 2003, Ethanol Alcohol 59-60, [filed as EX1078 in IPR2019-00451].	☐
16	"VALIUM: Brand of Diazepam Tablets" January 2008, Label, Roche 12 Pages, [filed as EX1080 in IPR2019-00451].	☐
17	VAN DER LUBBEN et al. "Chitosan and Its Derivatives in Mucosal Drug and Vaccine Delivery" 2001, European J. Pharmaceutical Sciences 14(3):201-207.	☐
18	VIDAL et al. "Making Sense of Antisense" November 9, 2005, European J. Cancer 41(18):2812-2818.	☐
19	WANG "Drug Delivery and Release System" August 2007, China Medical Science and Technology Press 9 Pages.	☒
20	WANG et al. "Factors Predictive of Outcome in Posttraumatic Seizures" 2008, The J. Trauma 64(4):883-888, [filed as EX1103 in IPR2019-00451].	☐
21	WATANABE et al. "Antibacterial Carbohydrate Monoesters Suppressing Cell Growth of Streptococcus Mutans in the Presence of Sucrose" 2000, Current Microbiology 41:210-213.	☐
22	WEBER et al. "Metabolism of Orally Administered Alkyl Beta-Glycosides in the Mouse" 1984, The J. Nutrition 114:247-254.	☐

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		18782666
Filing Date		2024-07-24
First Named Inventor	Steve CARTT	
Art Unit		
Examiner Name	Not Yet Assigned	
Attorney Docket Number		148570-014311

23	Webpage for Anatrace Products of Affymetrix, retrieved from the internet: http://www.affymetrix.com/estore/browse/level_three_category_and_products.jsp?category=35843&categoryIdClicked=35843&expand=true&parent=35900 Accessed online on (December 13, 2012) 2 Pages.	☐
24	WERMELING et al. "A pharmacokinetic and pharmacodynamic study, in healthy volunteers, of a rapidly absorbed intranasal midazolam formulation," February 2009, Epilepsy Res. 83(2-3):124-132.	☐
25	WERMELING et al. "Bioavailability and Pharmacokinetics of Lorazepam after Intranasal, Intravenous, and Intramuscular Administration" 2001, J .Clinical Pharmacology 41:1225-1231, [filed as EX1134 in IPR2019-00451].	☐
26	WERMELING et al. "Pharmacokinetics and Pharmacodynamics of a New Intranasal Midazolam Formulation in Healthy Volunteers" 2006, Anesthesia & Analgesia 103(2):344-349, XP002585302.	☐
27	WERMELING "Intranasal Delivery of Antiepileptic Medications for Treatment of Seizures" April 2009, Neurotherapeutics 6(2):352-358, [Filed as EX1151 in IPR2019-00451].	☐
28	WIKIPEDIA "Benzodiazepine Overdose" September 23, 2019, entire document, especially page 2 paragraph 1, retrieved from the internet: https://en.wikipedia.org/w/index.php?title=Benzodiazepine_overdose&oldid=917464003 (March 10, 2022) 10 Pages.	☐
29	WILSON et al. "Nasal/Buccal Midazolam Use in the Community" 2004, Archives of Disease in Childhood 59(1):50-51, [filed as EX1141 in IPR2019-00451].	☐
30	WOLFE et al. "Intranasal Midazolam Therapy for Pediatric Status Epilepticus" 2006, The American J. of Emergency Medicine, 24:343-346, [filed as EX1110 in IPR2019-00451].	☐
31	WOLFE "Intranasal Drug Delivery: An Alternative to Intravenous Administration in Selected Emergency Cases" April 2004, The J. Emergency Nursing 30(2):141-147, [filed as EX1145 in IPR2019-00451].	☐
32	WORRELL et al. "Focal Ictal Beta Discharge on Scalp EEG Predicts Excellent Outcome of Frontal Lobe Epilepsy Surgery" March 2002, Epilepsia 43(3):277-282, DOI: 10.1046/j.1528-1157.2002.37501.x, entire document, especially abstract.	☐
33	XINLEI et al. "Triptan Medicament And Migraine" 2001, World Pharmacy (Synthetic Drug and Biochemical Drug Formulation Fascicule) 22(2):91-92 - 6 Pages.	☒

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666
	Filing Date		2024-07-24
	First Named Inventor	Steve CARTT	
	Art Unit		
	Examiner Name	Not Yet Assigned	
	Attorney Docket Number		148570-014311

	34	YAMAMOTO et al. "The Ocular Route for Systemic Insulin Delivery in the Albino Rabbit" April 1989, J. Pharmacology and Experimental Therapeutics 249(1):249-255.	☐
--	----	---	--------------------------

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	18782666
Filing Date	2024-07-24
First Named Inventor	Steve CARTT
Art Unit	
Examiner Name	Not Yet Assigned
Attorney Docket Number	148570-014311

CERTIFICATION STATEMENT

Please see 37 CFR 1.97(e) to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☒ A certification statement is not submitted herewith.

FEE

☐ The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

COPIES

☒ An identification of an earlier application pursuant to 37 CFR 1.98 (d) (1) is attached.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/N. Nicole Endejann/	Date (YYYY-MM-DD)	2024-08-30
Name/Print	N. Nicole Endejann	Registration Number	50,229

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666
	Filing Date		2024-07-24
	First Named Inventor	Steve CARTT	
	Art Unit		
	Examiner Name	Not Yet Assigned	
	Attorney Docket Number		148570-014311

U.S.PATENTS							Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Patent citation information please click the Add button.							Add	
U.S.PATENT APPLICATION PUBLICATIONS							Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Published Application citation information please click the Add button.							Add	
FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							☐
If you wish to add additional Foreign Patent Document citation information please click the Add button								Add
NON-PATENT LITERATURE DOCUMENTS								Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						T ⁵

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666
	Filing Date		2024-07-24
	First Named Inventor	Steve CARTT	
	Art Unit		
	Examiner Name	Not Yet Assigned	
	Attorney Docket Number		148570-014311

1	LIU et al. "Interaction between Chitosan and Alkyl β -D-Glucopyranoside and its Effect on their Antimicrobial Activity" 2004, Carbohydrate Polymers 56:243-250.	☐
2	LOFTSSON et al. "Cyclodextrin Solubilization of Benzodiazepines: Formulation of Midazolam Nasal Spray" 2001, International Journal of Pharmaceutics 212:29-40, [filed as EX1125 in IPR2019-00451].	☐
3	LOGROSCINO et al. "Time Trends in Incidence, Mortality, and Case-Fatality after First Episode of Status Epilepticus" 2001, Epilepsia 42:1031-1035, [filed as EX1105 in IPR2019-00451].	☐
4	LOWENSTEIN et al. "It's Time to Revise the Definition of Status Epilepticus" 1999, Epilepsia 40(1):120-122, [filed as EX1102 in IPR2019-00451].	☐
5	LOWENSTEIN "Status Epilepticus" April 02, 1998, The New England J. Medicine 338:970-976, [Filed as EX1101 in IPR2019-00451].	☐
6	MAA et al. "Biopharmaceutical Powders: Particle Formation and Formulation Considerations" 2000, Current Pharmaceutical Biotechnology 1(3):283-302.	☐
7	MAHMOUDIAN et al. "Comparison of Intranasal Midazolam with Intravenous Diazepam for Treating Acute Seizures in Children" 2004, Brief Communication Epilepsy and Behavior 5:253-255, [filed as EX1138 in IPR2019-00451].	☐
8	MAITANI et al. "Design of Ocular/Lacrimal And Nasal Systems Through Analysis Of Drug Administration and Absorption" December 15, 1997, J. of Controlled Release 49(2-3):185-192, [filed as EX1045 in IPR2019-00451, PR2019-00450, IPR2019-00449].	☐
9	"Managing Epilepsy Well Network and Selected Self-Management Programs; Putting Collective Wisdom to Work for People with Epilepsy" November 2016, Prevention Research Centers (PRC), Centers for Disease Control and Prevention, 20 Pages, [Filed as EX2004 in IPR2019-00451, PR2019-00450, IPR2019-00449].	☐
10	MARK et al. "GLP-1: Target for a New Class of Antidiabetic Agents?" June 2004, J. Royal Society of Medicine 97 (6):270-274.	☐
11	Material Safety Data Sheet for Anatrace, Inc. product n-DODECYL-p-d-MALTOPYRANOSIDE, ANAGRADE, Dated: January 25, 1994 and Revised: 07/15/2004, Retrieved from the Internet: http://media.affymetrix.com/estore/browse/level_three)category_and_products.jsp?category=35843&categoryIdClicked=35843&expand=true&parent=35900 (December 13, 2012) 1 Page.	☐

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		18782666
Filing Date		2024-07-24
First Named Inventor	Steve CARTT	
Art Unit		
Examiner Name	Not Yet Assigned	
Attorney Docket Number		148570-014311

12	MATHEW. "Serotonin 1D (5-HT1D) Agonists and Other Agents in Acute Migraine" February 1997, Neurologic Clinics 15(1):61-83.	☐
13	MATSUMURA et al. "Surface Activities, Biodegradability and Antimicrobial Properties of n-alkyl Glucosides, Mannosides and Galactosides" December 1990, J. American Oil Chemists Society 67(12):996-1001.	☐
14	MEIERKORD et al. "EFNS Guideline on the Management of Status Epilepticus" 2006, European J. Neurology 13:445-450, [filed as EX1111 in IPR2019-00451].	☐
15	MERKUS et al. "Can Nasal Drug Delivery Bypass the Blood-Brain Barrier Questioning The Direct Transport Theory" 2007, Drugs 8:133-144, [filed as EX1117 in IPR2019-00451].	☐
16	MERKUS et al. "Influence of Anatomy and Head Position on Intranasal Drug Deposition" 2006 ,European Archives of Otorhinolaryngolog 263:827-832, [filed as EX1114 in IPR2019-00451].	☐
17	MEYERS et al. "Key Potentially Inappropriate Drugs in Pediatrics: The KIDs List" 2020, Journal of Pediatric Pharmacology and Therapeutics 25(3):175-191.	☐
18	MITRANO et al. "Factors Affecting Insulin Adherence To Type I Glass Bottles" 1982, American J. Hospital Pharmacy 39(9):1491-1495.	☐
19	MITTAL et al. "Comparative Study of Intranasal Midazolam and Intravenous Diazepam Sedation for Procedures and Seizures" 2006, Indian J. Pediatrics 73:975-978, (filed as EX1137 in IPR2019-00451).	☐
20	MOSES et al. "Insulin Administered Intranasally As An Insulin-bite Salt Aerosol - Effectiveness And Reproducibility In Normal And Diabetic Subjects" November 1983, Diabetes 32: 1040-1047.	☐
21	MURAKAMI et al. "Assessment of Enhancing Ability of Medium-Chain Alkyl Saccharides as New Absorption Enhancers in Rat Rectum" February 1992, International J. Pharmaceutics 79(1-3):159-169.	☐
22	MYGIND "Nasal Allergy 2nd Ed." 1979, 9, Blackwell Scientific Publications, 3 Pages, [filed as EX2022 in IPR2019-00451].	☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666
	Filing Date		2024-07-24
	First Named Inventor	Steve CARTT	
	Art Unit		
	Examiner Name	Not Yet Assigned	
	Attorney Docket Number		148570-014311

	23	Nayzilam Product Label and Instructions for Use Revised May 2019, 28 Pages, [filed as EX1072 in IPR2019-00451].	☐
	24	"Neurelis Files New Drug Application With The FDA For Valtoco (Diazepam Nasal Spray), An Investigational Treatment For Pediatric, Adolescent And Adult Epilepsy Patients" 2018, (November 01, 2019) 2 Pages, [filed as EX2023 in IPR2019-00451].	☐
	25	"Neurelis Receives FDA Orphan Drug Designation for NRL-1 In The Treatment of Acute Repetitive Seizures" December 22, 2015, retrieved from the internet: https://www.neurelis.com/neurelis-news/fda-orphan-drug-designation (November 01, 2019), 2 Pages, [filed as EX2024 in IPR2019-00451].	☐
	26	NEWMAN "Aerosol Deposition Consideration In Inhalation Therapy," 1985, Chest, 152S-160S.	☐
	27	Non Final Office Action mailed 01 October 2013 for U.S. Application No. 13/495,942, 9 Pages.	☐
	28	Non Final Office Action mailed 02 April 2013 for U.S. Application No. 12/116,842, 18 Pages.	☐
	29	Non Final Office Action mailed 05 July 2016 for U.S. Application No. 14/152,686, 7 Pages.	☐
	30	Non Final Office Action mailed 05 October 2015 for U.S. Application No. 12/413,439, 11 Pages.	☐
	31	Non Final Office Action mailed 07 October 2019 for U.S. Application No. 15/955,397, 8 pages.	☐
	32	Non Final Office Action mailed 08 July 2015 for U.S. Application No. 12/116,842, 17 Pages.	☐
	33	Non Final Office Action mailed 12 April 2018 for U.S. Application No. 15/470,498, 7 pages.	☐

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		18782666
Filing Date		2024-07-24
First Named Inventor	Steve CARTT	
Art Unit		
Examiner Name	Not Yet Assigned	
Attorney Docket Number		148570-014311

	34	Non Final Office Action mailed 12 September 2019 for U.S. Application No. 15/470,498, 12 pages.	☐
	35	Non Final Office Action mailed 14 July 2016 for U.S. Application No. 14/527,613, 27 pages.	☐
	36	Non Final Office Action mailed 15 February 2018 for U.S. Application No. 14/948,081, 26 Pages.	☐
	37	Non Final Office Action mailed 16 November 2011 for U.S. Application No. 12/266,529, 22 Pages.	☐
	38	Non Final Office Action mailed 18 March 2011 for U.S. Application No. 12/413,439, 14 pages.	☐
	39	Non Final Office Action mailed 19 June 2014 for U.S. Application No. 12/413,439, 8 Pages.	☐
	40	Non Final Office Action mailed 22 May 2015 for U.S. Application No. 14/021,988, 23 Pages.	☐
	41	Non Final Office Action mailed 25 May 2011 for U.S. Application No. 12/116,842, 21 Pages.	☐
	42	Non Final Office Action mailed 26 September 2012 for U.S. Application No. 13/371,274, 18 Pages.	☐
	43	Non Final Office Action mailed 30 March 2017 for U.S. Application No. 12/413,439, 12 pages.	☐
	44	Non Final Office Action mailed 31 December 2014 for U.S. Application No. 14/152,686, 41 Pages.	☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666
	Filing Date		2024-07-24
	First Named Inventor	Steve CARTT	
	Art Unit		
	Examiner Name	Not Yet Assigned	
	Attorney Docket Number		148570-014311

	45	Non Final Office Action mailed 31 October 2016 for U.S. Application No. 14/948,081, 17 Pages.	☐
	46	Non Final Office Action mailed 14 February 2023 for U.S. Application No. 17/570,535, 27 Pages.	☐
	47	Notice Forwarding Certified List, filed 18 November 2020 in Appeal Case No. 21-1038, Court of Appeals for the Federal Circuit, 81 Pages.	☐
	48	Notification of Receipt of Precedential Opinion Panel (POP) Request of U.S. Patent No. 9,763,876, filed 02 October 2019 in IPR2019-00451, 2 Pages.	☐
	49	O'DELL et al. "School Nurses' Experience With Administration of Rectal Diazepam Gel For Seizures" June 2007, J. School Nursing 23(3):166-169 [filed as EX1029 in IPR2019-00451, IPR2019-00450, IPR2019-00449].	☐
	50	O'DONNELL et al. "Therapeutic Potential of a Long Acting Somatostatin Analogue in Gastrointestinal Diseases" 1989, Gut 30(9):1165-1172.	☐

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666
	Filing Date		2024-07-24
	First Named Inventor	Steve CARTT	
	Art Unit		
	Examiner Name	Not Yet Assigned	
	Attorney Docket Number		148570-014311

CERTIFICATION STATEMENT

Please see 37 CFR 1.97(e) to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☒ A certification statement is not submitted herewith.

FEE

☐ The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

COPIES

☒ An identification of an earlier application pursuant to 37 CFR 1.98 (d) (1) is attached.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/N. Nicole Endejann/	Date (YYYY-MM-DD)	2024-08-30
Name/Print	N. Nicole Endejann	Registration Number	50,229

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666
	Filing Date		2024-07-24
	First Named Inventor	Steve CARTT	
	Art Unit		
	Examiner Name	Not Yet Assigned	
	Attorney Docket Number		148570-014311

U.S.PATENTS Remove						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	3102116	A	1963-08-27	CHASE; George	
	2	3109843	A	1963-11-05	REEDER; Earl et al.	
	3	3136815	A	1964-06-09	REEDER; Earl et al.	
	4	3243427	A	1966-03-29	REEDER; Earl et al.	
	5	3296249	A	1967-01-03	BELL; Stanley C.	
	6	3299053	A	1967-01-17	ARCHER; Giles A. et al.	
	7	3340253	A	1967-09-05	REEDER; Earl et al.	
	8	3371085	A	1968-02-27	REEDER; Earl et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666	
	Filing Date		2024-07-24	
	First Named Inventor	Steve CARTT		
	Art Unit			
	Examiner Name	Not Yet Assigned		
	Attorney Docket Number		148570-014311	

	9	3374225	A	1968-03-19	REEDER; Earl et al.	
	10	3547828	A	1970-12-15	MANSFIELD; Richard C. et al.	
	11	3567710	A	1971-03-02	FRYER; Rodney et al.	
	12	3609145	A	1971-09-28	MOFFETT; Robert B.	
	13	3722371	A	1973-03-27	BOYLE; Robert F.	
	14	3849341	A	1974-11-19	LAMBERTI; V. et al.	
	15	3949072	A	1976-04-06	TENTA; Louis T.	
	16	3987052	A	1976-10-19	HESTER, Jr.; Jackson B.	
	17	4130709	A	1978-12-19	NAGARAJAN; Ramakrishnan	
	18	4280957	A	1981-07-28	WALSER et al.	
	19	4397951	A	1983-08-09	TAKI et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666	
	Filing Date		2024-07-24	
	First Named Inventor	Steve CARTT		
	Art Unit			
	Examiner Name	Not Yet Assigned		
	Attorney Docket Number		148570-014311	

	20	4440675	A	1984-04-03	BRAUDE; Irwin A.	
	21	4608278	A	1986-08-26	FRANK et al.	
	22	4657901	A	1987-04-14	UEDA et al.	
	23	4690952	A	1987-09-01	KAGATANI et al.	
	24	4748158	A	1988-05-31	BIERMANN et al.	
	25	4826689	A	1989-05-02	VIOLANTO; Michael R.	
	26	4868289	A	1989-09-19	MAGNUSSON et al.	
	27	4921838	A	1990-05-01	CATSIMPOOLAS et al.	
	28	4973465	A	1990-11-27	BAURAIN et al.	
	29	4997454	A	1991-03-05	VIOLANTE et al.	
	30	5091188	A	1992-02-25	HAYNES; Duncan H.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666	
	Filing Date		2024-07-24	
	First Named Inventor	Steve CARTT		
	Art Unit			
	Examiner Name	Not Yet Assigned		
	Attorney Docket Number		148570-014311	

	31	5100591	A	1992-03-31	LECLEF et al.	
	32	5118528	A	1992-06-02	FESSI et al.	
	33	5122187	A	1992-06-16	SCHWARZ et al.	
	34	5145684	A	1992-09-08	LIVERSIDGE et al.	
	35	5182258	A	1993-01-26	CHIOU; George C. Y.	
	36	5188837	A	1993-02-23	DOMB; Abraham J.	
	37	5192528	A	1993-03-09	RADHAKRISHNAN et al.	
	38	5198420	A	1993-03-30	DONAHOE et al.	
	39	5236707	A	1993-08-17	STEWART, II; William E.	
	40	5268461	A	1993-12-07	SHOJI et al.	
	41	5308531	A	1994-05-03	URFER et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666	
	Filing Date		2024-07-24	
	First Named Inventor	Steve CARTT		
	Art Unit			
	Examiner Name	Not Yet Assigned		
	Attorney Docket Number		148570-014311	

	42	5317010	A	1994-05-31	PANG et al.	
	43	5369095	A	1994-11-29	KEE et al.	
	44	5457100	A	1995-10-10	DANIEL; David G.	
	45	5550220	A	1996-08-27	MEYER et al.	
	46	5556757	A	1996-09-17	ALSTYNE et al.	
	47	5556940	A	1996-09-17	WILLICK et al.	
	48	5560932	A	1996-10-01	BAGCHI et al.	
	49	5639733	A	1997-06-17	KOIKE et al.	
	50	5661130	A	1997-08-26	MEEZAN et al.	
	51	5662883	A	1997-09-02	BAGCHI et al.	
	52	5665331	A	1997-09-09	BAGCHI et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666	
	Filing Date		2024-07-24	
	First Named Inventor	Steve CARTT		
	Art Unit			
	Examiner Name	Not Yet Assigned		
	Attorney Docket Number		148570-014311	

	53	5716642	A	1998-02-10	BAGCHI et al.	
	54	5738845	A	1998-04-14	IMAKAWA; Kazuhiko	
	55	5780062	A	1998-07-14	FRANK et al.	
	56	5789375	A	1998-08-04	MUKAE et al.	
	57	5795896	A	1998-08-18	LOFROTH et al.	
	58	5814607	A	1998-09-29	PATTON; John S.	
	59	5817634	A	1998-10-06	MEEZAN et al.	
	60	5831089	A	1998-11-03	HUBER; Joel E.	
	61	5849884	A	1998-12-15	WOISZWILLO; James E. et al.	
	62	5861510	A	1999-01-19	PISCOPIO et al.	
	63	5863949	A	1999-01-26	ROBINSON et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666	
	Filing Date		2024-07-24	
	First Named Inventor	Steve CARTT		
	Art Unit			
	Examiner Name	Not Yet Assigned		
	Attorney Docket Number		148570-014311	

	64	5955425	A	1999-09-21	MORLEY et al.	
	65	5981719	A	1999-11-09	WOISZWILLO et al.	
	66	6004574	A	1999-12-21	BACKSTROM et al.	
	67	6090925	A	2000-07-18	WOISZWILLO et al.	
	68	6143211	A	2000-11-07	MATHIOWITZ et al.	
	69	6165484	A	2000-12-26	RAAD et al.	
	70	6193985	B1	2001-02-27	SONNE; Mette Rydahl	
	71	6235224	B1	2001-05-22	MATHIOWITZ et al.	
	72	6254854	B1	2001-07-03	EDWARDS et al.	
	73	6268053	B1	2001-07-31	WOISZWILLO et al.	
	74	6316029	B1	2001-11-13	JAIN et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666	
	Filing Date		2024-07-24	
	First Named Inventor	Steve CARTT		
	Art Unit			
	Examiner Name	Not Yet Assigned		
	Attorney Docket Number		148570-014311	

	75	6316410	B1	2001-11-13	BARBIER et al.	
	76	6375986	B1	2002-04-23	RYDE et al.	
	77	6395300	B1	2002-05-28	STRAUB et al.	
	78	6428814	B1	2002-08-06	BOSCH et al.	
	79	6458387	B1	2002-10-01	SCOTT et al.	
	80	6461591	B1	2002-10-08	KELLER et al.	
	81	6482516	B1	2002-11-19	SADEK et al.	
	82	6482834	B2	2002-11-19	SPADA et al.	
	83	6495498	B2	2002-12-17	NIEMIEC et al.	
	84	6524557	B1	2003-02-25	BACKSTROM et al.	
	85	6551578	B2	2003-04-22	ADJEI et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666	
	Filing Date		2024-07-24	
	First Named Inventor	Steve CARTT		
	Art Unit			
	Examiner Name	Not Yet Assigned		
	Attorney Docket Number		148570-014311	

	86	6583616	B1	2003-06-24	BOMYA; Timothy J.	
	87	6607784	B2	2003-08-19	KIPP et al.	
	88	6608073	B1	2003-08-19	HUSSAIN et al.	
	89	6610271	B2	2003-08-26	WERMELING; Daniel P.	
	90	6616914	B2	2003-09-09	WARD et al.	
	91	6627211	B1	2003-09-30	CHOI et al.	
	92	6794357	B1	2004-09-21	BACKSTROM et al.	
	93	6855332	B2	2005-02-15	GIZURARSON et al.	
	94	6869617	B2	2005-03-22	KIPP et al.	
	95	6884436	B2	2005-04-26	KIPP et al.	
	96	6908626	B2	2005-06-21	COOPER et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666	
	Filing Date		2024-07-24	
	First Named Inventor	Steve CARTT		
	Art Unit			
	Examiner Name	Not Yet Assigned		
	Attorney Docket Number		148570-014311	

	97	6932962	B1	2005-08-23	BACKSTROM et al.	
	98	6991785	B2	2006-01-31	FREY, II; William H.	
	99	7008920	B2	2006-03-07	KIMURA et al.	
	100	7037528	B2	2006-05-02	KIPP et al.	
	101	7132112	B2	2006-11-07	CHOI et al.	
	102	7220402	B1	2007-05-22	ANDERSEN et al.	
	103	7425542	B2	2008-09-16	MAGGIO; Edward T.	
	104	7434579	B2	2008-10-14	YOUNG et al.	
	105	7524510	B2	2009-04-28	ARNOLD et al.	
	106	8530463	B2	2013-09-10	CARTT; Steve et al.	
	107	8895546	B2	2014-11-25	CARTT et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666	
	Filing Date		2024-07-24	
	First Named Inventor	Steve CARTT		
	Art Unit			
	Examiner Name	Not Yet Assigned		
	Attorney Docket Number		148570-014311	

	108	8927497	B2	2015-01-06	MAGGIO; Edward T.	
	109	9192570	B2	2015-11-24	WYSE et al.	
	110	9642913	B2	2017-05-09	MAGGIO; Edward T.	
	111	9763876	B2	2017-09-19	CARTT; Steve et al.	
	112	10265402	B2	2019-04-23	MAGGIO; Edward T.	
	113	11241414	B2	2022-02-08	CARTT; Steve et al.	
	114	11793786	B2	2023-10-24	CARTT; Steve et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS

Remove

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20010042932	A1	2001-11-22	MATHIOWITZ; Edith et al.	
	2	20020110524	A1	2002-08-15	COWAN; Siu Man L. et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666
	Filing Date		2024-07-24
	First Named Inventor	Steve CARTT	
	Art Unit		
	Examiner Name	Not Yet Assigned	
	Attorney Docket Number		148570-014311

	3	20020127278	A1	2002-09-12	KIPP; James E. et al.	
	4	20020141971	A1	2002-10-03	FREY, II; William H.	
	5	20020168402	A1	2002-11-14	KIPP; James E. et al.	
	6	20030017203	A1	2003-01-23	CROTTS; George et al.	
	7	20030031719	A1	2003-02-13	KIPP; James E. et al.	
	8	20030040497	A1	2003-02-27	TENG; Ching-Leou et al.	
	9	20030087820	A1	2003-05-08	YOUNG; Andrew A. et al.	
	10	20030095928	A1	2003-05-22	McGURK; Simon et al.	
	11	20030100755	A1	2003-05-29	SHAM; Hing Leung et al.	
	12	20030118547	A1	2003-06-26	VANDENBERG; Grant William	
	13	20030118594	A1	2003-06-26	NAG; Bishwajit et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666	
	Filing Date		2024-07-24	
	First Named Inventor	Steve CARTT		
	Art Unit			
	Examiner Name	Not Yet Assigned		
	Attorney Docket Number		148570-014311	

	14	20030158206	A1	2003-08-21	BILLOTTE; Anne et al.	
	15	20030170206	A1	2003-09-11	RASMUSSEN; Poul Baad et al.	
	16	20030170752	A1	2003-09-11	ANDERSEN; Thomas T. et al.	
	17	20030181411	A1	2003-09-25	BOSCH; H. William et al.	
	18	20040101482	A1	2004-05-27	SANDERS; Mark	
	19	20040115135	A1	2004-06-17	QUAY; Steven C.	
	20	20040126358	A1	2004-07-01	WARNE; Nicholas W. et al.	
	21	20040141923	A1	2004-07-22	DUGGER, III; Harry A. et al.	
	22	20040147473	A1	2004-07-29	WARRELL, Jr.; Raymond P.	
	23	20040176359	A1	2004-09-09	WERMELING; Daniel P.	
	24	20040209814	A1	2004-10-21	NAUCK; Michael A. et al.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		18782666
Filing Date		2024-07-24
First Named Inventor	Steve CARTT	
Art Unit		
Examiner Name	Not Yet Assigned	
Attorney Docket Number		148570-014311

	25	20040248846	A1	2004-12-09	QUAY; Steven C. et al.	
	26	20040258663	A1	2004-12-23	QUAY; Steven C. et al.	
	27	20050130260	A1	2005-06-16	LINDEN; Lars et al.	
	28	20050153956	A1	2005-07-14	MERKUS; Franciscus Wilhelmus Henricus Maria	
	29	20050215475	A1	2005-09-29	ONG; John et al.	
	30	20050234101	A1	2005-10-20	STENKAMP; Dirk et al.	
	31	20050276843	A1	2005-12-15	QUAY; Steven C. et al.	
	32	20060045868	A1	2006-03-02	MEEZAN; Elias et al.	
	33	20060045869	A1	2006-03-02	MEEZAN; Elias et al.	
	34	20060046962	A1	2006-03-02	MEEZAN; Elias et al.	
	35	20060046969	A1	2006-03-02	MAGGIO; Edward	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		18782666
Filing Date		2024-07-24
First Named Inventor	Steve CARTT	
Art Unit		
Examiner Name	Not Yet Assigned	
Attorney Docket Number		148570-014311

	36	20060074025	A1	2006-04-06	QUAY; Steven C. et al.	
	37	20060106227	A1	2006-05-18	REDDY; Manne Satyanarayana et al.	
	38	20060147386	A1	2006-07-06	WERMELING; Daniel P.	
	39	20060178290	A1	2006-08-10	BARA; Isabelle	
	40	20060183674	A1	2006-08-17	BRAND; Stephen J. et al.	
	41	20060198896	A1	2006-09-07	LIVERSIDGE; Gary et al.	
	42	20070059254	A1	2007-03-15	SINGH; Nikhilesh N.	
	43	20070098805	A1	2007-05-03	LIVERSIDGE; Gary G.	
	44	20070111938	A1	2007-05-17	PERT; Candace B. et al.	
	45	20070298010	A1	2007-12-27	MAGGIO; Edward T.	
	46	20080070904	A1	2008-03-20	JAMIESON; Gene et al.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		18782666
Filing Date		2024-07-24
First Named Inventor	Steve CARTT	
Art Unit		
Examiner Name	Not Yet Assigned	
Attorney Docket Number		148570-014311

	47	20080076761	A1	2008-03-27	JAMIESON; Gene et al.	
	48	20080194461	A1	2008-08-14	MAGGIO; Edward T.	
	49	20080200418	A1	2008-08-21	MAGGIO; Edward T.	
	50	20080248123	A1	2008-10-09	SWANSON; Jon et al.	
	51	20080268032	A1	2008-10-30	MAGGIO; Edward T.	
	52	20080275030	A1	2008-11-06	GIZURARSON; Sveinbjorn et al.	
	53	20080279784	A1	2008-11-13	CARTT; Steve et al.	
	54	20080299079	A1	2008-12-04	MEEZAN; Elias et al.	
	55	20090004281	A1	2009-01-01	NGHIEM; Tien et al.	
	56	20090047234	A1	2009-02-19	TOUITOU; Elka et al.	
	57	20090047347	A1	2009-02-19	MAGGIO; Edward T.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666	
	Filing Date		2024-07-24	
	First Named Inventor	Steve CARTT		
	Art Unit			
	Examiner Name	Not Yet Assigned		
	Attorney Docket Number		148570-014311	

	58	20090130216	A1	2009-05-21	CARTT; Steve et al.	
	59	20090156478	A1	2009-06-18	LAU; Jesper et al.	
	60	20090163447	A1	2009-06-25	MAGGIO; Edward T.	
	61	20090258865	A1	2009-10-15	CARTT; Steve et al.	
	62	20090297619	A1	2009-12-03	SWANSON; Jon et al.	
	63	20090304801	A1	2009-12-10	LIVERSIDGE; Gary et al.	
	64	20090326193	A1	2009-12-31	MAGGIO; Edward T. et al.	
	65	20100068209	A1	2010-03-18	MAGGIO; Edward T.	
	66	20100112050	A1	2010-05-06	RYOO; Je Phil et al.	
	67	20100160378	A1	2010-06-24	MAGGIO; Edward T.	
	68	20100203014	A1	2010-08-12	MAGGIO; Edward T.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		18782666
Filing Date		2024-07-24
First Named Inventor	Steve CARTT	
Art Unit		
Examiner Name	Not Yet Assigned	
Attorney Docket Number		148570-014311

	69	20100203119	A1	2010-08-12	LEANE; Michael et al.	
	70	20100209485	A1	2010-08-19	MAGGIO; Edward T.	
	71	20110038899	A1	2011-02-17	GWOZDZ; Garry Thomas et al.	
	72	20110172211	A1	2011-07-14	BAEK; Myoung-Ki et al.	
	73	20110257096	A1	2011-10-20	MAGGIO; Edward T.	
	74	20120196941	A1	2012-08-02	MAGGIO; Edward T.	
	75	20130065886	A1	2013-03-14	CARTT; Steve et al.	
	76	20130224300	A1	2013-08-29	MAGGIO; Edward T.	
	77	20130253009	A1	2013-09-26	MAGGIO; Edward T.	
	78	20140128479	A1	2014-05-08	MAGGIO; Edward T.	
	79	20140170220	A1	2014-06-19	CARTT; Steve et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666	
	Filing Date		2024-07-24	
	First Named Inventor	Steve CARTT		
	Art Unit			
	Examiner Name	Not Yet Assigned		
	Attorney Docket Number		148570-014311	

	80	20150065491	A1	2015-03-05	CARTT; Steve et al.	
	81	20160199296	A1	2016-07-14	BERGENHEM; Nils et al.	
	82	20170196884	A1	2017-07-13	CARTT; Steve et al.	
	83	20180235929	A1	2018-08-23	CARTT; Steve et al.	
	84	20200038320	A1	2020-02-06	CARTT; Steve et al.	
	85	20210299089	A1	2021-09-30	CARTT; Steve et al.	
	86	20220117887	A1	2022-04-21	CARTT; Steve et al.	
	87	20220241187	A1	2022-08-04	CARTT; Steve et al.	
	88	20230104144	A1	2023-04-06	CARTT; Steve et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button. [Add](#)

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666	
	Filing Date		2024-07-24	
	First Named Inventor	Steve CARTT		
	Art Unit			
	Examiner Name	Not Yet Assigned		
	Attorney Docket Number		148570-014311	

	1	1303674	CN	A	2001-07-18	INST OF MEDICAL INDUSTRY SHAND	with English Abstract	☒
	2	0396777	EP	A1	1990-11-14	OTSUKA PHARMA CO LTD		☐
	3	0606046	EP	A1	1994-07-13	CIBA GEIGY AG		☐
	4	0780386	EP	A1	1997-06-25	HOFFMANN LA ROCHE, et al.		☐
	5	0818442	EP	A2	1998-01-14	PFIZER		☐
	6	0931788	EP	A2	1999-07-28	PFIZER LTD, et al.		☐
	7	0945485	EP	A1	1999-09-29	MORTON INT INC		☐
	8	1004578	EP	A2	2000-05-31	PFIZER PROD INC		☐
	9	1208863	EP	A2	2002-05-29	UNISIA JECS CORP		☐
	10	1417972	EP	A1	2004-05-12	LILLY CO ELI		☐
	11	2003505403	JP	A	2003-02-12	SK CORP	with English Abstract and Equivalent US6627211B1	☒

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666	
	Filing Date		2024-07-24	
	First Named Inventor	Steve CARTT		
	Art Unit			
	Examiner Name	Not Yet Assigned		
	Attorney Docket Number		148570-014311	

	12	2005508939	JP	A	2005-04-07	ELAN PHARMA INT LTD	with English Equivalent US6908626B2	☒
	13	2007510722	JP	A	2007-04-26	ELAN PHARMA INT LTD	with English Equivalent US7879360B2	☒
	14	2009515895	JP	A	2009-04-16	WINCH PETER D	with English Equivalent WO2007059019A2	☒
	15	2011516425	JP	A	2011-05-26	HALE BIOPHARMA VENTURES, LLC	with English Equivalent WO2009121039A2	☒
	16	6883918	JP	B2	2021-06-09	HALE BIOPHARMA VENTURES, LLC	with English Equivalent US9763876B2	☒
	17	H01151528	JP	A	1989-06-14	TAIHO PHARMACEUTICAL CO LTD.	with English Abstract	☒
	18	H05507085	JP	A	1993-10-14	NOVO NORDISK AS	with English Abstract and Equivalent WO1991016929A1	☒
	19	H0583918	JP	B2	1993-11-30	INTERNATL BUSINESS MACH CORP IBM	with English Abstract	☒
	20	S60208911	JP	A	1985-10-21	GREEN CROSS CORP	with English Abstract	☒
	21	S61267528	JP	A	1986-11-27	YAMANOUCHI PHARMA CO LTD.	with English Equivalent US6627211B1	☒
	22	1990005719	WO	A1	1990-05-31	BRITISH BIO TECHNOLOGY		☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666	
	Filing Date		2024-07-24	
	First Named Inventor	Steve CARTT		
	Art Unit			
	Examiner Name	Not Yet Assigned		
	Attorney Docket Number		148570-014311	

	23	1991019481	WO	A1	1991-12-26	ALLERGAN INC		☐
	24	1994005262	WO	A1	1994-03-17	FAULDING F H & CO LTD, et al.		☐
	25	1995000151	WO	A1	1995-01-05	UAB RESEARCH FOUNDATION		☐
	26	1995031217	WO	A1	1995-11-23	DUMEX LTD AS, et al.		☐
	27	1996027583	WO	A1	1996-09-12	PFIZER, et al.		☐
	28	1996033172	WO	A1	1996-10-24	PFIZER, et al.		☐
	29	1997014407	WO	A1	1997-04-24	RES TRIANGLE PHARM LTD, et al.		☐
	30	1998003516	WO	A1	1998-01-29	PFIZER, et al.		☐
	31	1998007697	WO	A1	1998-02-26	PFIZER, et al.		☐
	32	1998030566	WO	A1	1998-07-16	PFIZER, et al.		☐
	33	1998033768	WO	A1	1998-08-06	PFIZER PROD INC, et al.		☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666	
	Filing Date		2024-07-24	
	First Named Inventor	Steve CARTT		
	Art Unit			
	Examiner Name	Not Yet Assigned		
	Attorney Docket Number		148570-014311	

	34	1998034915	WO	A1	1998-08-13	PFIZER, et al.		☐
	35	1998034918	WO	A1	1998-08-13	PFIZER, et al.		☐
	36	1999007675	WO	A1	1999-02-18	PFIZER PROD INC, et al.		☐
	37	1999029667	WO	A1	1999-06-17	PFIZER LTD, et al.		☐
	38	1999052889	WO	A1	1999-10-21	PFIZER PROD INC, et al.		☐
	39	1999052910	WO	A1	1999-10-21	PFIZER PROD INC, et al.		☐
	40	2000001390	WO	A1	2000-01-13	RECORDATI CHEM PHARM, et al.		☐
	41	2000074681	WO	A1	2000-12-14	PFIZER LTD, et al.		☐
	42	2003004015	WO	A1	2003-01-16	WEST PHARM SERV DRUG RES LTD, et al.		☐
	43	2003007978	WO	A1	2003-01-30	ALBANY MEDICAL COLLEGE		☐
	44	2003055464	WO	A1	2003-07-10	BESINS INT BELGIQUE, et al.	with English Abstract	☒

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666	
	Filing Date		2024-07-24	
	First Named Inventor	Steve CARTT		
	Art Unit			
	Examiner Name	Not Yet Assigned		
	Attorney Docket Number		148570-014311	

	45	2005018565	WO	A2	2005-03-03	TRANSORAL PHARMACEUTICALS INC, et al.		☐
	46	2005044234	WO	A2	2005-05-19	ELAN PHARMA INT LTD, et al.		☐
	47	2005089768	WO	A1	2005-09-29	UNIV KENTUCKY RES FOUND, et al.		☐
	48	2005117830	WO	A1	2005-12-15	CAMURUS AB, et al.		☐
	49	2006025882	WO	A2	2006-03-09	UAB RESEARCH FOUNDATION, et al.		☐
	50	2006051110	WO	A2	2006-05-18	NOVO NORDISK AS, et al.		☐

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

NON-PATENT LITERATURE DOCUMENTS

Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	Affidavit of Robert Cleary executed November 21, 2019 [filed as EX2025 in IPR2019-00451].	☐
	2	Affidavit of Ronald Figueroa executed November 21, 2019 [filed as EX2026 in IPR2019-00451].	☐
	3	AGARWAL et al. "A Pilot Study Assessing the Bioavailability and Pharmacokinetics of Diazepam after Intranasal and Intravenous Administration in Healthy Volunteers" 2013, Epilepsy Research 105:362-367.	☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666
	Filing Date		2024-07-24
	First Named Inventor	Steve CARTT	
	Art Unit		
	Examiner Name	Not Yet Assigned	
	Attorney Docket Number		148570-014311

4	AHMAD et al. "Efficacy and Safety of Intranasal Lorazepam Versus Intramuscular Paraldehyde for Protracted Convulsions in Children: an Open Randomised Trial" May 13, 2006, Lancet 367:1591-1597, [filed as EX1144 in IPR2019-00451].	☐
5	AHSAN et al. "Sucrose Cocoate, a Component of Cosmetic Preparations, Enhances Nasal and Ocular Peptide Absorption" 2003, International J. Pharmaceutics 251(1-2):195-203.	☐
6	AHSAN F., et al., "Effects of the permeability enhancers, tetradecylmaltoside and dimethyl- β -cyclodextrin, on insulin movement across human bronchial epithelial cells," European Journal of Pharmaceutical Sciences, 2003, Vol. 20, pp. 27-34.	☐
7	ALBERT et al. "Pharmacokinetics of Diphenhydramine in Man" 1975, J. Pharmacokinetics and Biopharmaceutics, 3 (3):159-170.	☐
8	Appellant Neurelis Inc.'s Opening Brief filed 02 February 2021 in Appeal Case No. 21-1038, Court of Appeals for the Federal Circuit, 184 Pages.	☐
9	Appellant Neurelis Inc.'s Reply Brief filed 03 May 2021 in Appeal Case No. 21-1038 (Court of Appeals for the Federal Circuit), 25 Pages.	☐
10	ARNOLD et al. "Correlation Of Tetradecylmaltoside Induced Increases In Nasal Peptide Drug Delivery With Morphological Changes In Nasal Epithelial Cells" September 2004, Journal of Pharmacy and Pharmaceutical Sciences 93(9):2205-2213.	☐
11	Assignment of U.S. Patent Application Serial No. 12/116,842 recorded at REEL: 027955 FRAME: 0600, on 29 March 2012, 3 Pages, [filed Jan. 29, 2019 as EX1049 in IPR2019-00451].	☐
12	Assignment of U.S. Patent Application Serial No. 12/933,701 recorded at REEL: 025034 FRAME: 0531, on 23 September 2010, 5 Pages, [filed as EX1047 in IPR2019-00451, IPR2019-00450, IPR2019- 00449].	☐
13	Australia First Examination Report of Australia Patent Application No. 2009228093, dated 19 July 2013, 02 pages.	☐
14	BEAM et al. "Blood, Brain, Cerebrospinal Fluid Concentrations of Several Antibiotics in Rabbits with Intact and Inflamed Meninges" December 1977, Antimicrobial Agents and Chemotherapy 12(6):710-716.	☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666
	Filing Date		2024-07-24
	First Named Inventor	Steve CARTT	
	Art Unit		
	Examiner Name	Not Yet Assigned	
	Attorney Docket Number		148570-014311

15	BECHGAARD et al. "Solubilization of Various Benzodiazepines for Intranasal Administration, a Pilot Study" 1997, Pharmaceutical Development and Technology 2:293-296, [Filed as EX2007 in IPR2019-00451].	☐
16	BEHL et al. "Effects of Physicochemical Properties And Other Factors On Systemic Nasal Drug Delivery" 1998, Advanced Drug Delivery Reviews 29: 89-116, [Filed as EX1039 in IPR2019- 00451, IPR2019-00450, IPR2019-00449].	☐
17	BERROCOSO et al. "Opiates as Antidepressants" 2009, Current Pharmaceutical Design 15:1612-1622.	☐
18	BHAIRI "A Guide to the Properties and Uses of Detergents in Biological Systems" 2001, Calbiochem, 1-42.	☐
19	BHATTACHARYYA et al. "Intranasal Midazolam vs Rectal Diazepam in Acute Childhood Seizures" 2006, Pediatric Neurologies 34:355-359, [filed as EX1140 in IPR2019-00451].	☐
20	BIRKETT et al. "Bioavailability and First Pass Clearance" 1991, Australian Prescriber 14:14-16.	☐
21	BIRKETT et al. "How Drugs are Cleared by the Liver" 1990, Australian Prescriber 13(4):88-89.	☐
22	BROWN "Affinity Purification of a Somatostatin Receptor-G-Protein Complex Demonstrates Specificity in Receptor-G-Protein Coupling" March 25, 1993, J. Biological Chemistry 268(9):6668-6676.	☐
23	BUDAVARI et al. "The Merck Index" 1996, Editors, 12th Edition 14 Pages [filed as EX1076 in IPR2019-00451].	☐
24	BURSTEIN et al. "Pharmacokinetics and Pharmacodynamics of Midazolam after Intranasal Administration" 1997, J. Clinical Pharmacology 37:711-718, [filed as EX1129 in IPR2019-00451].	☐
25	Canada Office Action in Canadian Application No. 2723470, mailed February 19, 2015, 5 Pages.	☐

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	18782666
Filing Date	2024-07-24
First Named Inventor	Steve CARTT
Art Unit	
Examiner Name	Not Yet Assigned
Attorney Docket Number	148570-014311

26	Canada Office Action in Canadian Application No. 2723470, mailed June 07, 2012, 3 Pages.	☐
27	Canada Office Action in Canadian Application No. 2756690, mailed 19 February 2015, 05 pages.	☐
28	Canada Office Action in Canadian Application No. 2756690, mailed 20 October 2015, 03 pages.	☐
29	CASTRO et al. "Ecologically Safe Alkyl Glucoside-Based Gemini Surfactants" 2005, Issue in Honor of Prof Rosa LederKremer, ARKIVOC, xii 253-267, ISSN 1424-6376.	☐
30	CDER 2019-09-19-Abbreviated Approval Products: 505(b)(2) or ANDA, 2019, Retrieved from URL: https://www.fda.gov/drugs/cder-small-business-industry-assistance-sbia/abbreviated-approval-pathways-drug-product-505b2-or-and-september-19-2019-issue , [filed as EX1147 in IPR2019-00451].	☐
31	CHAVANPATIL et al. "Nasal Drug Delivery of Sumatriptan Succinate" May 2005, Pharmazie 60(5):347-349.	☐
32	CHEN et al. "Peptide Drug Permeation Enhancement by Select Classes of Lipids" December 10-14, 2005, Presented at the 45th American Society of Cell Biology, S.F., CA, 01 Page.	☐
33	CHEN-QUAY et al. "Identification of Tight Junction Modulating Lipids" February 2009, J. Pharmaceutical Sciences 98 (2):606-619, retrieved from the internet: www.interscience.wiley.com (June 18, 2008).	☐
34	CHIEN et al. "Nasal Systemic Drug Delivery" 1989, Anatomy and Physiology of the Nose, Drugs and the Pharmaceutical Sciences, Marcel Decker Chapter 1 39:29 Pages, [filed as EX1082 in IPR2019-00451].	☐
35	Chinese Office Action for application no. CN 200980157305.0, dated January 28, 2013.	☐
36	Chinese Office Action for Chinese Application No. 201280039077.9, dated 11 August 2015, 10 Pages.	☒

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		18782666
Filing Date		2024-07-24
First Named Inventor	Steve CARTT	
Art Unit		
Examiner Name	Not Yet Assigned	
Attorney Docket Number		148570-014311

37	Chinese Office Action for Chinese Application No. 201280039077.9, dated 17 March 2016, 6 Pages.	☐
38	Chinese Office Action for Chinese Application No. 201280039077.9, dated 21 November 2016, 05 pages.	☒
39	Chinese Office Action for Chinese Application No. 201280039077.9, dated 26 December 2014, 11 pages, [With English Translation].	☒
40	Chinese Office Action for Chinese Application No. 201710940124.1 dated 25 November 2019, 14 Pages.	☒
41	Chinese Office Action for Chinese Application No. 201710940124.1, dated 28 September 2020, 10 Pages.	☒
42	Chinese Reexamination Notification for Chinese Application No. 201280039077.9, dated 29 June 2017, 5 Pages.	☐
43	CHIOU et al. "Improvement of Systemic Absorption of Insulin Through Eyes with Absorption Enhancers" October 1989, J. Pharmaceutical Sciences 78(10):815-818.	☐
44	CHIOU et al. "Systemic Delivery of Insulin Through Eyes to Lower the Glucose Concentration" 1989, J. Ocular Pharmacology 5(1):81-91.	☐
45	CHRISTENSEN et al. "Once-Weekly GLP-1 Agonists: How Do They Differ from Exenatide and Liraglutide" 2010, Current Diabetes Reports 10(2):124-132.	☐
46	COLE et al. "Community Survey of Carers: Individual Epilepsy Guidelines (IEG) for Rescue Medication" 2009, Seizure 18:220-224, [filed as EX2015 in IPR2019-00451].	☐
47	COLOMBO et al. "Mucosal Drug Delivery, Nasal" Encyclopedia of Controlled Drug Delivery (Mathiowitz, editor), John Wiley & Sons, Vol. 2 (1999): 592-605 [filed as EX1037 in IPR2019- 00451, IPR2019-00450, IPR2019-00449].	☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666
	Filing Date		2024-07-24
	First Named Inventor	Steve CARTT	
	Art Unit		
	Examiner Name	Not Yet Assigned	
	Attorney Docket Number		148570-014311

48	Complaint filed May 8, 2024 in U.S. District Court of Delaware, Neurelis, Inc. v. Padagis LLC et al., Case 1:24-cv-00562-MN (D. Del) (15 pages).	☐
49	CORBO et al. "Measurement of Nasal Mucociliary Clearance" 1989, Archives of Disease in Childhood 64:546-550 (filed as EX2020 in IPR2019-00451).	☐
50	Corrected Brief for Appellee Aquestive Therapeutics, Inc., filed 31 March 2021, in Appeal Case No. 21-1038, Court of Appeals for the Federal Circuit, 81 Pages.	☐

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	18782666
Filing Date	2024-07-24
First Named Inventor	Steve CARTT
Art Unit	
Examiner Name	Not Yet Assigned
Attorney Docket Number	148570-014311

CERTIFICATION STATEMENT

Please see 37 CFR 1.97(e) to make the appropriate selection(s):

- ☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).
- OR**
- ☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).
- ☐ See attached certification statement.
- ☒ A certification statement is not submitted herewith.

FEE

- ☐ The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

COPIES

- ☒ An identification of an earlier application pursuant to 37 CFR 1.98 (d) (1) is attached.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/N. Nicole Endejann/	Date (YYYY-MM-DD)	2024-08-30
Name/Print	N. Nicole Endejann	Registration Number	50,229

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666
	Filing Date		2024-07-24
	First Named Inventor	Steve CARTT	
	Art Unit	1612	
	Examiner Name	Michael P. COHEN	
	Attorney Docket Number	148570-014311	

U.S.PATENTS							Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Patent citation information please click the Add button.							Add	
U.S.PATENT APPLICATION PUBLICATIONS							Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	20060222597	A1	2006-10-05	DUGGER, Harry			
If you wish to add additional U.S. Published Application citation information please click the Add button.							Add	
FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							☐
If you wish to add additional Foreign Patent Document citation information please click the Add button								Add
NON-PATENT LITERATURE DOCUMENTS								Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						T ⁵

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666
	Filing Date		2024-07-24
	First Named Inventor	Steve CARTT	
	Art Unit	1612	
	Examiner Name	Michael P. COHEN	
	Attorney Docket Number	148570-014311	

1	LI et al. "Development of an ethyl laurate-based microemulsion for rapid-onset intranasal delivery of diazepam" 2002, Int J Pharmaceutics, 237:77-85.	☐
---	---	--------------------------

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666
	Filing Date		2024-07-24
	First Named Inventor	Steve CARTT	
	Art Unit		1612
	Examiner Name	Michael P. COHEN	
	Attorney Docket Number		148570-014311

CERTIFICATION STATEMENT

Please see 37 CFR 1.97(e) to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☒ See attached certification statement.

☐ A certification statement is not submitted herewith.

FEE

☐ The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

COPIES

☐ An identification of an earlier application pursuant to 37 CFR 1.98 (d) (1) is attached.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Marissa S. Kuzirian/	Date (YYYY-MM-DD)	2024-11-25
Name/Print	Marissa S. Kuzirian, Ph.D.	Registration Number	78,983

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666
	Filing Date		2024-07-24
	First Named Inventor	Steve CARTT	
	Art Unit	1612	
	Examiner Name	Michael P. COHEN	
	Attorney Docket Number	148570-014311	

U.S.PATENTS							Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Patent citation information please click the Add button.							Add	
U.S.PATENT APPLICATION PUBLICATIONS							Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Published Application citation information please click the Add button.							Add	
FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							☐
If you wish to add additional Foreign Patent Document citation information please click the Add button								Add
NON-PATENT LITERATURE DOCUMENTS								Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						T ⁵

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		18782666
	Filing Date		2024-07-24
	First Named Inventor	Steve CARTT	
	Art Unit	1612	
	Examiner Name	Michael P. COHEN	
	Attorney Docket Number	148570-014311	

1	Li et al. "Rapid-onset intranasal delivery of anticonvulsants: pharmacokinetic and pharmacodynamic evaluation in rabbits" 2000, Int J Pharmaceutics, 199:65-76.	☐
---	---	--------------------------

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	18782666
Filing Date	2024-07-24
First Named Inventor	Steve CARTT
Art Unit	1612
Examiner Name	Michael P. COHEN
Attorney Docket Number	148570-014311

CERTIFICATION STATEMENT

Please see 37 CFR 1.97(e) to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☒ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☒ See attached certification statement.

☐ A certification statement is not submitted herewith.

FEE

☐ The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

COPIES

☐ An identification of an earlier application pursuant to 37 CFR 1.98 (d) (1) is attached.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Marissa S. Kuzirian/	Date (YYYY-MM-DD)	2024-12-12
Name/Print	Marissa S. Kuzirian, Ph.D.	Registration Number	78,983

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	18782666
	Filing Date	2024-07-24
	First Named Inventor	Steve CARTT
	Art Unit	1612
	Examiner Name	Michael P. COHEN
	Attorney Docket Number	148570-014311

U.S. PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Inventor of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information, please click the Add button.

Add

U.S. PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Inventor or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Published Application citation information, please click the Add button

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							☐

If you wish to add additional Foreign Patent Document citation information, please click the Add button

Add

NON-PATENT LITERATURE DOCUMENTS				Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number		18782666
	Filing Date		2024-07-24
	First Named Inventor	Steve CARTT	
	Art Unit		1612
	Examiner Name	Michael P. COHEN	
	Attorney Docket Number		148570-014311

1	Declaration of Dr. Maureen Donovan, Ph.D.	☐
2	Petition for Inter Partes Review of U.S. Patent No. 11,241,414 filed January 17, 2025 in IPR2025-00465.	☐
3	Petition for Inter Partes Review of U.S. Patent No. 11,793,786 filed January 17, 2025 in IPR2025-00466.	☐
4	Petition for Inter Partes Review of U.S. Patent No. 8,895,546 filed January 17, 2025 in IPR2025-00464.	☐
5	Preliminary Invalidity Contentions filed December 20, 2024, in Neurelis, Inc. v. Padagis LLC et al., Civil Action No. 24-562 (MN) (D. Delaware).	☐
6	SHARMA et al. "Permeation enhancers in the transmucosal delivery of macromolecules" 2006, Pharmazie, 61 (6):495-504.	☐

If you wish to add additional non-patent literature document citation information, please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

***EXAMINER:** Initial if reference considered and whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number		18782666
	Filing Date		2024-07-24
	First Named Inventor	Steve CARTT	
	Art Unit		1612
	Examiner Name	Michael P. COHEN	
	Attorney Docket Number		148570-014311

TIMING STATEMENT			
Please see 37 CFR 1.97(e) to make the appropriate selection(s):			
☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).			
OR			
☒ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).			
☒ See attached timing statement under 37 CFR 1.97(e).			
☐ A timing statement under 37 CFR 1.97(e) is not submitted herewith.			
TIMING FEE			
☐ The fee set forth in 37 CFR 1.17(p) has been submitted herewith.			
COPIES			
☐ An identification of an earlier application pursuant to 37 CFR 1.98(d)(1) is attached.			
SIZE FEE ASSERTION			
Please see 37 CFR 1.17(v) and the IDS Auto-Load Instructions for completing this form to make the appropriate selection of an assertion under 37 CFR 1.98. For the information disclosure statement (IDS) submitted herewith, the applicant or patent owner certifies the following with respect to the cumulative number of applicant-provided or patent-owner provided items of information submitted to date including those in the accompanying IDS (select only one):			
☒ No IDS size fee is required under 37 CFR 1.17(v) at this time.			
☐ The IDS is accompanied by the IDS size fee under 37 CFR 1.17(v)(1).			
☐ The IDS is accompanied by the IDS size fee under 37 CFR 1.17(v)(2).			
☐ The IDS is accompanied by the IDS size fee under 37 CFR 1.17(v)(3).			
SIGNATURE			
A signature of the applicant or representative is required in accordance with 37 CFR 1.33 and 11.18. Please see 37 CFR 1.4(d) for the form of the signature.			
Signature	/Marissa S. Kuzirian/	Date (YYYY-MM-DD)	2025-02-03
Name/Print	Marissa S. Kuzirian, Ph.D.	Registration Number	78,983

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number	18782666
Filing Date	2024-07-24
First Named Inventor	Steve CARTT
Art Unit	1612
Examiner Name	Michael P. COHEN
Attorney Docket Number	148570-014311

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.